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Growing evidences have indicated an important role of central nervous system 
(CNS) lipid mediators and reactive nitrogen species (RNS) in augmenting the sensitivity 
of sensory neurons and enhancing pain perception. Increased amount of ceramide which 
is an important sphingolipid signaling molecule and elevated ceramide biosynthetic 
activity have been shown to contribute to neuronal death in the hippocampus after 
kainate-induced excitotoxic injury. RNS species such as peroxynitrite (ONOO-) and its 
derivates can cause lipid oxidation, protein nitration, and DNA damage, leading to 
changes in the function of signaling molecules.  
Intracerebroventricular (ICV) injection of inhibitors to ceramide synthetic 
enzymes into mice was conducted to elucidate possible role of CNS ceramide in orofacial 
pain induced by facial carrageenan injection. ICV injection of inhibitors to acid 
sphingomyelinase (ASMase), neutral sphingomyelinase (NSMase), or serine 
palmitoyltransferase (SPT) significantly reduced allodynic responses in facial 
carrageenan injected mice.  
An enzyme activity assay was conducted in the mice brain tissue. Increased 
ASMase activity was found in the left primary somatosensory cortex at 3 days after facial 
carrageenan injection. And ICV injection of ASMase inhibitor D609 significantly 
reduced ASMase activity in all parts of brain examined (i.e., left and right brain stem, 
thalamus, and primary somatosensory cortex). These results provide a further 







Since D609 is also found to be a free radical scavenger, 
phenyl-N-tert-butylnitrone (PBN), a free radical spin trap was ICV injected to elucidate 
the role of free radicals in nociception. Similar anti-allodynic effect was observed in mice 
with facial allodynia after PBN treatment. It was also found that C18 ceramide could 
cause increased hydrogen peroxide production in PC12 cells. This effect could be 
inhibited by co-treatment with L-type calcium inhibitor (nifedipine), free radical 
scavengers (D609 or PBN), or mitochondria permeability transition pore blockers 
(bongkrekic acid or cyclosporine A).  
Electrophysiological study showed that ceramide has the ability to directly induce 
exocytosis in cells using membrane capacitance measurement technique (whole-cell 
patch clamp) and total internal reflection fluorescence microscopy technique. Effects of 
ceramide were found to be dependent on the integrity of cell membrane lipid raft, as 
ceramide could not induce exocytosis in cells depleted of membrane cholesterol. Direct 
application of ceramide can also cause elevated intracellular calcium concentration in 
PC12 cells. 
The role of other forms of free radicals such as peroxynitrite in orofacial allodynia 
was also investigated. Mice behavioral studies showed that ONOO- plays a role in 
nociception in the CNS in mice with facial allodynia. ICV injection of ONOO- scavenger 
FeTPPS significantly reduced allodynia in the facial carrageenan injected mice at 3 days 
after injection.  
In conclusion, the present study showed a possible role of CNS ceramide and 
ONOO- in a mouse model of orofacial allodynia.
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1. General introduction of pain 
1.1. History of pain study and pain definitions  
Pain is defined by the International Association for the Study of Pain (IASP, 2008) 
as “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or describe in terms of such damage”. It is a protective mechanism for the 
body and causes a human or animal to take action to remove the pain stimulus. 
The earliest scientific history of pain transmission should be René Descartes' 
reflex theory more than 300 years ago, which proposed a specific pain pathway which 
carries the information from pain receptors in the peripheral skin to pain center in the 
brain, indicating that a simple block of the pathway would result in the alleviation of pain. 
The pain measurement at that time was focused on the pain intensity. Descartes’ reflex 
theory guided both the study and treatment of pain for centuries till the appearance of the 
gate control theory of pain (Melzack and Wall 1965), which led to a further investigation 
into spinal sensitization and central nervous system (CNS) plasticity. The main 
achievement of the gate control theory of pain is that it led to the recognition that the 
relationship between pain and stimulus is not a simple sensory response, the processing 
of pain takes place in at least three levels — at peripheral, spinal, and supraspinal sites. 
However, recently more studies showed that pain perception is not a mere biophysical 
process, it is always subjective and influenced by a variety of complicated factors. For 
example, acute pain can be proportional to the extent of the injury, but also be affected by 
psychological factors, such as fear, anxiety, cultural background and the meaning of the 
situation to the person (Sternbach 1975). 
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A few definitions of pain-related terms are clarified here: Nociception is defined 
as the neural process of encoding and processing noxious stimuli (Loeser and Treede 
2008). It is the afferent activity produced in the peripheral and CNS by stimuli that have 
the potential to damage tissue. The term “nociception” is often used interchangeably with 
the term “pain”, but technically refers to the transmission of nociceptive information to 
the brain without reference to the production of emotional or other types of response to 
the noxious stimulus. Nociceptor is a receptor preferentially sensitive to a noxious 
stimulus or to a stimulus which would become noxious if prolonged. The most often used 
two behavioral tests in pain studies are hyperalgesia and allodynia. Hyperalgesia is the 
increased response to a stimulus which is normally painful. For pain evoked by stimuli 
that usually are not painful, the term allodynia is preferred. Allodynia is defined as pain 
due to a stimulus which does not normally provoke pain. In addition, the difference 
between hyperalgesia and allodynia can also be elucidated in terms of pain 
hypersensitivity which takes two forms: thresholds are lowered so that stimuli that would 
normally not produce pain now begin to — allodynia; Responsiveness is increased, so 
that noxious stimuli produce an exaggerated and prolonged pain — hyperalgesia.   
 Other somatosensory disorders of increased pain sensation which are often seen 
in the literature include hyperesthesia, hyperpathia and neuropathy. Hyperesthesia is 
defined as increased sensitivity to stimulation, excluding the special senses. 
Hyperesthesia may refer to various modes of cutaneous sensibility including touch and 
thermal sensation without pain, as well as to pain. Hyperesthesia includes both allodynia 
and hyperalgesia. Hyperpathia is defined as a painful syndrome characterized by an 
abnormally painful reaction to a stimulus, especially a repetitive stimulus, as well as an 
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increased threshold. Neuropathy is a disturbance of function or pathological change in a 
nerve (IASP, 2008).  
1.2. Types of pain  
 Depending on the nature and time course of the original stimulus, there are three 
major types of pain that have different neurophysiological mechanisms. However, it is 
important to know that these types are not exclusive. 
1.2.1. Type 1 (Acute nociceptive pain)  
The mechanism of type 1 of pain can be viewed as a simple and direct route of 
transmission centrally toward the thalamus and cortex and subsequently the conscious 
perception of pain, however there still has possibility of modulation at synaptic relays 
along the pathway. It is suggested that it is best to use models based on the specificity 
interpretation of pain mechanisms to explain type 1 pain, that is, the existence within the 
peripheral and CNS of a series of neuronal elements concerned solely with the processing 
of these simple noxious elements. 
1.2.2. Type 2 (Inflammatory pain)  
If a noxious stimulus is very intense or prolonged, leading to tissue damage and 
inflammation, the afferent flow to the CNS from the injured nociceptors will increase 
because of the elevated activity and responsiveness of sensitized nociceptors. And 
nociceptive neurons in the spinal cord also modify their responsiveness in ways that are 
not merely an expression of the peripheral stimulations.  
The subject with type 2 pain can feel spontaneous pain in the injured area, as well 
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as the undamaged area surrounding the injury site. This changed sensation is known as 
hyperalgesia, defined as a leftward shift in the stimulus-response function (Figure 1.1). In 
this situation, normally innocuous stimuli such as brushing and touch, are painful 
(allodynia), and normally mild pain stimuli like pinprick are much more painful than 
usual (hyperalgesia). Hyperalgesia in the area of injury is also known as primary 
hyperalgesia, and the abnormal pain in the “normal” tissue surrounding the damaged site 
is defined as secondary hyperalgesia. 
 
Figure 1.1 Diagram illustrating the changes in pain sensation induced by injury. 
The normal relationship between stimulus intensity and magnitude of pain 
sensation is represented by the curve. Pain sensation is only evoked by stimulus 
intensities in the noxious range (the vertical dotted line indicates the pain 
threshold). The leftward shift in the curve relating stimuli intensity to pain 
sensation is called hyperalgesia. Under these conditions, innocuous stimuli 
evoke pain (allodynia), and stimuli intensities that normally evoke mild pain 
evoke more intense pain (Cervero and Laird 1996). 
1.2.3. Type 3 (Neuropathic pain)  
This type of pain is abnormal and is generally the consequence of damage to 
peripheral nerves or CNS itself, characterized by a lack of correlation. These pains are 
spontaneous, triggered by innocuous stimuli, or are exaggerated responses to noxious 
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minor stimuli. These sensations are expressions of substantial changes in the nociception 
system induced by peripheral or central damages. 
1.3. Primary and central sensitization  
On the one hand, pain hypersensitivity as an adaptive response facilitates the 
healing process after an injury because it avoids or minimizes the direct contact with the 
injured tissue until repair is complete. On the other hand, pain hypersensitivity may 
persist long after an injury has healed or occur in the absence of any injury. In this case, 
pain turns to a manifestation of pathological change in the nervous system.  
Two mechanisms are known to be involved in pain hypersensitivity — peripheral 
and central sensitization. “Sensitization” here means the increase in the excitability of 
neurons, so they are more sensitive to stimuli or sensory inputs.  
1.3.1. Peripheral sensitization 
Peripheral sensitization refers to a reduction in threshold and an increase in the 
sensitivity and excitability of the nociceptors terminal (Treede et al. 1992; Julius and 
Basbaum 2001). Peripheral sensitization contributes to pain hypersensitivity at the site of 
tissue damage and inflammation, a phenomenon which is also called primary 
hyperalgesia.  
Peripheral sensitization results from the release of numerous inflammatory factors 
and changes of ion channels in the nociceptor terminal. The inflammatory factors include 
prostaglandins, adenosine triphosphate (ATP) (Gold et al. 1996), bradykinin (Chahl and 
Iggo 1977; Cui and Nicol 1995), nerve growth factor (NGF), potassium, leukotrienes, 
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serotonins, substance P, histamines, thromboxanes, serotonin/5-hydroxytryptamine (5-HT) 
(Cardenas et al. 2001; Okamoto et al. 2002), endothelin-1 (Gokin et al. 2001; Zhou et al. 
2002), platelet-activating factor, protons and free radicals. For example, increased level 
of substance P is found in the periphery after nerve injury (Donnerer et al. 1993; Carlton 
et al. 1996). It has been observed that intrathecal injection of substance P, or its close 
analogues, can produce hyperalgesia to a variety of noxious stimuli (Cridland and Henry 
1986).  
These inflammatory mediators could phosphorylate G-protein-coupled receptors 
or tyrosine kinase receptors on nociceptor terminals, activating phospholipase C signaling 
pathways. Among these receptors, transient receptor potential receptor (TRP) is the one 
that has been well studied. TRPV1 (transient receptor potential receptor, subfamily V, 
member 1) can be activated by noxious heat, acid, capsaicin and resiniferatoxin, leading 
to burning pain or itch. It is found that NGF and bradykinin can induce changes in 
TRPV1 by activating of cAMP-dependent (cyclic adenosine monophosphate-dependent) 
protein kinase and Ca2+/phospholipid-dependent kinase, so that a lower temperature 
(<40 °C) which normally could not activate TRPV1 can now activate this receptor 
(Chuang et al. 2001).  
Transcriptional or translational regulation also contributes to peripheral 
sensitization. It is found that NGF-induced activation of p38 mitogen-activated protein 
kinase (MAPK) in primary sensory neurons after peripheral inflammation increases the 
expression and peripheral transport of TRPV1, exacerbating heat hyperalgesia (Ji et al. 
2002). There is evidence that in small DRG (dorsal root ganglia) cells, NGF has the 
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ability to stimulate an upregulation of NaV1.8, a sensory neuron-specific voltage-gated 
sodium channel (Bielefeldt et al. 2003). 
1.3.2. Central sensitization  
Central sensitization refers to the increase in the excitability of CNS neurons, so 
that normal stimuli produce abnormal responses. Central sensitization is responsible for 
tactile allodynia (pain in response to light brushing of the skin) and for the spread of pain 
hypersensitivity resulting in increased susceptibility of tissue adjacent to damaged area, a 
phenomenon often termed as “secondary hyperalgesia” (Sang et al. 1996; Klede et al. 
2003). Many studies on secondary hyperalgesia were conducted with capsaicin, which 
selectively acts on several types of fine sensory C and Aδ-fibers. Capsaicin causes 
intense pain and secondary hyperalgesia when applied topically or intradermally (Simone 
et al. 1989).  
Central sensitization has two phases: An immediate but relatively transient phase 
and a slower onset but longer-lasting phase. Central sensitization is associated with 
enhanced responses to excitatory amino acids and decreased responses to inhibitory 
amino acids. The mechanism of the increase in responses to excitatory amino acids 
includes phosphorylation of NR1 subunits of N-methyl-D-aspartate (NMDA) receptors 
and GluR1 subunits of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) 
receptors (Willis 2009).  
In the early phase of central sensitization, signaling molecules including 
glutamate, neuropeptides [eg., substance P and calcitonin gene related peptide (CGRP)] 
and synaptic modulators are released from synapses in the spinal cord upon receiving 
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signals from the nociceptors, activating intracellular signaling pathways that could lead to 
the phosphorylation of membrane receptors and channels, especially NMDA (Cheng et al. 
2008) and AMPA receptors. Glutamate plays a major role in the process of central 
sensitization (DeLeo 2006). These changes could increase the efficacy of synaptic 
transmission between primary and secondary neurons in the nociception pathway, 
thereby increasing the excitability of the neurons. Central sensitization also depends on 
activation of several protein kinases and other enzymes, such as nitric oxide synthase. 
This process is regulated by protein phosphatases. Central sensitization can be regarded 
as a spinal cord form of long-term potentiation (Willis 2009).  
The later phase of central sensitization is transcription-dependent. It is mediated 
by increased protein production. Proteins involved in this process include dynorphin 
(Malan et al. 2000; Ossipov et al. 2000), an endogenous opioid that increases neuronal 
excitability, and cyclooxygenase-2 (COX-2) (Burns et al. 2006; Levy et al. 2008), the 
enzyme that produces prostaglandin E2.  
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2. General introduction of orofacial pain 
Similar brain structures are involved in the process of nociception and related 
expression of nociceptive behaviors in humans and animal models (Chang and Shyu 
2001). For example, trigeminal sensory nuclei are involved in nociceptive activity in 
orofacial pain. Lesions or injections of analgesic chemicals into these levels can interfere 
with nociceptive behavior (Takemura et al. 1993).  
2.1. Anatomy basis of orofacial pain  
2.1.1. Trigeminal nerves 
Trigeminal nerve (the fifth cranial nerve) is primarily a sensory nerve, it also has 
certain motor functions such as biting, chewing, and swallowing. Trigeminal nerve has 
three divisions according to the different innervation area. They are ophthalmic, 
maxillary and mandibular division (Figure 1.2). Each division supplies to a distinct area 
on the head, face, the adjacent mucosal and meningeal tissues (Usunoff et al. 1997).  
The ophthalmic nerve innervates the forehead, upper eyelid, cornea and 
conjunctiva, dorsum of the nose, mucous membranes of the nasal vestibule and frontal 
sinus, and the cranial dura. The maxillary nerve innervates the lower eyelid, anterior 
portion of the temple, paranasal sinuses, upper lip and cheek, nose, oral mucosa of the 
upper mouth, pharynx, gums, maxillary teeth, hard palate, soft palate, and cranial dura. 
The mandibular nerve has both sensory and motor components. The motor mandibular 
component innervates the muscles of mastication, the temporalis, masseter, lateral and 
medial pterygoids, mylohyoid, the anterior belly of the digastric muscle, the tensors 
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tympani and veli palatini. The sensory component of mandibular nerve innervates the 
lower lip and chin, posterior portion of the temple, external auditory meatus and 
tympanic membrane, external ear teeth of the lower jaw, oral mucosa of the cheeks and 
the floor of the mouth, anterior two thirds of the tongue, temporomandibular joint and 
cranial dura.  
  
Figure 1.2 Dermatome distribution of the trigeminal nerve (modified from 
Hinrichsen, 2008). 
2.1.2. Trigeminal ganglion 
The three branches of trigeminal nerve converge on the trigeminal ganglion, 
which contains cell bodies of incoming sensory nerve fibers. Fibers from trigeminal 
ganglion project to different trigeminal nucleus in brain stem. The trigeminal ganglion 
lies in the Meckel’s cave in the dura mater near the apex of the petrous part of the 
temporal bone. Ganglion cells are pseudounipolar and their somata are tightly wrapped 
by satellite cells, with some showing complex interdigitations with neuronal membrane 
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A large number of peptides are known to be present in the trigeminal ganglion. 
These include calcitonin gene related peptide (CGRP), substance P, somatostatin, galanin 
and enkephalins (Del Fiacco and Quartu 1994; Quartu and Del Fiacco 1994). It has been 
found that CGRP exists in the majority of neurons from rat trigeminal ganglia, together 
with exocytotic SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor) and synaptotagmin (Meng et al. 2007). Nearly half the human ganglion cells 
contain CGRP, and around 15% containing substance P, and some showing 
co-localization of these two (Helme and Fletcher 1983; Quartu et al. 1992).  
2.1.3. Sensory trigeminal nucleus 
Sensory fibers from trigeminal nerve as well as other cranial nerves— facial nerve 
(cranial nerve VII), glossopharyngeal nerve (cranial nerve IX) and vagus nerve (cranial 
nerve X) terminate in the trigeminal nucleus, which thus contains a complete sensory 
map of the face and mouth. The trigeminal nucleus extends throughout the entire brain 
stem, from the midbrain to the medulla, continues into the spinal cord and merges with 
the dorsal horn cells. The nucleus is divided anatomically into three parts. From caudal to 
rostral, they are the spinal trigeminal nucleus, the main trigeminal nucleus, and the 
mesencephalic trigeminal nucleus (Figure 1.3).  
The major neural transmitter throughout the sensory complex is glutamate, with 
NMDA and non-NMDA receptors at all levels (Magnusson et al. 1987; Tallaksen-Greene 
et al. 1992; Petralia et al. 1994). In addition, peptides such as substance P and CGRP are 
also important neural transmitters in the sensory trigeminal nucleus (Sessle 2000). 
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Figure 1.3 Distribution of sensory trigeminal nucleus (modified from Snell 
2006). 
Spinal trigeminal nucleus 
The spinal trigeminal nucleus receives fibers carrying pain/temperature sensation 
from the face, i.e., fibers from cranial nerves V, VII, IX, and X. These fibers are grouped 
together and can be identified as the spinal tract of the trigeminal nucleus, which parallels 
the spinal trigeminal nucleus itself. The spinal trigeminal nuclei are further subdivided 
into three groups— oralis (Sp5O), interpolaris (Sp5I) and caudalis (Sp5C) (Capra and 
Dessem 1992). From the spinal trigeminal nucleus, secondary fibers cross the midline 
and ascend via the trigeminothalamic tract to the contralateral thalamus. The 
trigeminothalamic tract runs parallel to the spinothalamic tract carrying pain/temperature 
Principal 
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sensation from rest of the body. Besides the thalamus, the spinal trigeminal nucleus also 
sends pain/temperature information to the mesencephalon and the reticular formation of 
the brainstem.  
It has been proposed Sp5O is particularly important for processing information 
about short duration nociceptive stimuli, whereas Sp5C is more important for processing 
tonic nociceptive information (Raboisson et al. 1995). Clinical findings are consistent 
with results from animal experiments indicating that Sp5C is the most important 
component of the trigeminal nuclear complex for perception of noxious stimuli applied to 
craniofacial region (Broton et al. 1988; Dohrn et al. 1994; Sessle 2000). The afferents 
terminating in Sp5C contain neuropeptides and amino acids that have been implicated as 
excitatory neurotransmitters or neuromodulators (e.g. substance P, glutamate, nitric oxide) 
in central nociceptive transmission (Sessle 2000). For instance, NK1, an antagonist of the 
substance P receptor, blocks c-fos expression induced by noxious chemical stimulation of 
dural afferents (Shepheard et al. 1995).  
Main trigeminal nucleus 
The principal or main trigeminal nucleus (Pr5) receives touch/position sensation 
from face via cranial nerves V, VII, IX, and X. It is located in the pons, close to the entry 
site of the trigeminal nerve. Animal studies have shown that neurons in Pr5 are 
mechanoreceptive with low thresholds and small receptive fields (Jacquin et al. 1988). 
From the main trigeminal nucleus, secondary fibers cross the midline and ascend in the 
trigeminal lemniscus to the contralateral thalamus. The trigeminal lemniscus runs parallel 
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to the medial lemniscus carrying touch/position information from the rest of the body to 
the thalamus. 
Some sensory information from the teeth and jaws is also projected from the main 
trigeminal nucleus to the ipsilateral thalamus, via the small dorsal trigeminal tract. Thus 
touch/position information from the teeth and jaws is represented bilaterally in the 
thalamus, and hence in the cortex (Brodal 2004).  
Mesencephalic trigeminal nucleus 
The mesencephalic trigeminal nucleus is not a real “nucleus.” It is actually a 
sensory ganglion imbedded in the brainstem. Only certain types of sensory fibers have 
cell bodies in the mesencephalic nucleus: proprioceptor fibers from the jaw, and 
mechanoreceptor fibers from the teeth. Some of these incoming fibers go to the motor 
trigeminal nucleus, thus entirely bypassing the pathways for conscious perception. Other 
incoming fibers from the teeth and jaws go to the main trigeminal nucleus. As mentioned 
above, these information are projected bilaterally to the thalamus, and then to the cortex 
for conscious perception (Brodal 2004). 
2.1.4. Pathways to the thalamus and the cortex 
The ventral posterolateral nucleus (VPL) nucleus of the thalamus receives 
touch/position information from the body, while touch/position information from the face 
is sent to the ventral posteromedial nucleus (VPM) nucleus of the thalamus. Information 
from VPL and VPM is then projected to the primary somatosensory cortex (SI) in the 
postcentral gyrus of the parietal lobe. Information from SI is sent to the secondary 
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somatosensory cortex (SII) in the parietal lobe. In general, information from one side of 
the body is represented on the opposite side in SI, but on both sides in SII (Brodal 2004).   
Pain/temperature information is also sent to the VPL (body) and VPM (face) of 
the thalamus. From the thalamus, both pain/temperature and touch/position information is 
projected onto SI. The main difference between touch/position and pain/temperature 
sensation transmission is that the latter is also sent to additional thalamic nuclei and areas 
of cortex. Some pain/temperature fibers are sent to the medial dorsal thalamic nucleus, 
then to the anterior cingulate cortex. Other fibers are relayed to the ventromedial nucleus 
of the thalamus, then to the insular cortex. Finally, some fibers are sent to the 
intralaminar nuclei of the thalamus via the reticular formation. The intralaminar nuclei 
projections diffuse to all parts of the cerebral cortex (Brodal 2004). 
2.2. Orofacial pain 
The diagnosis of orofacial pain is complicated because of the region’s density of 
anatomical structures, rich innervations and high vascularity. Orofacial pain is defined by 
the American Academy of Orofacial Pain (AAOP) as “pain conditions that are associated 
with the hard and soft tissues of the head, face, neck, and all the intraoral structures” 
(Okeson 1996). Most prevalent pain in this area originates from the teeth and their 
surrounding structures. Pain from these areas can be caused by local injury resulting from 
trauma, infection or neoplasms.  
The ill-defined category of atypical oral and facial pain includes a variety of pain 
descriptions like phantom tooth pain (Turp 2005), atypical odontalgia (Grushka et al. 
2003; Baad-Hansen et al. 2005), atypical facial neuralgia (Marbach et al. 1982; Aguggia 
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2005), and the burning mouth syndrome (Grushka et al. 2003). The pain in these cases 
usually has a burning quality that occasionally intensifies to produce throbbing sensation. 
The pain is not triggered by remote stimuli, but may be intensified by stimulation of the 
affected area itself. 
2.3. Animal model of orofacial pain 
The understanding of neural mechanisms of both acute and chronic pain 
syndromes has been improved a lot by the usage of animal models. These animal models 
provide quantitative assessments of hypersensitivity that are correlated to pain in human. 
Although currently it is not possible to scientifically prove whether an animal is in pain 
or not and how painful they are, it can still be inferred from physical and behavioral 
reactions. 
Acute inflammatory pain models normally involve injection of an irritant 
substance into a joint or hind paw of animals. The chronic neuropathic pain models 
usually involve surgical manipulation of a nerve. Behavioral testing approaches can be 
classified by the method of stimulation (thermal, chemical, or mechanical) and by the 
type of stimulus (noxious compared with non-noxious). The two behavioral tests that are 
most often used in chronic pain studies are hyperalgesia (increased sensitivity to a 
noxious stimulus) and allodynia (increased sensitivity to a non-noxious stimulus). 
Reactions produced by a noxious stimulus can fall into two categories— responses 
organized by lower hierarchical areas of the CNS, such as withdrawal reflexes and 
cardiovascular changes, and more integrated complex responses requiring supraspinal 
input, such as tactile hypersensitivity or learned conditioned responses (DeLeo 2006).  
 
 Chapter I  Introduction 






Figure 1.4 Responses of different mouse strains to different behavioral 
measures of nociception. Genotype significantly affected the performance in 
nociceptive measures. No mice strain is consistently highest or lowest in these 
assays (Mogil et al. 1999). 
Standard evaluation methods currently in use include the hot-plate and tail-flick 
tests (Le Bars et al. 2001) and the use of von Frey hair to assess mechanical allodynia. 
Models of inflammation that produce more persistent pain include the injection of 
carrageenan or complete Freud’s adjuvant into the footpad (Iadarola et al. 1988) or into 
the joint of the limb of animals (Schaible et al. 1987), or facial carrageenan injections 
(Ng and Ong 2001; Yeo et al. 2004; Vahidy et al. 2006).  
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Increasing attention has been paid to behavior genetics of the laboratory animals, 
especially mice. It has been found to have a great deal of response variability to 
mechanical, chemical or thermal stimulus among different mouse strains (Figure 1.4) 
(Mogil et al. 1999). In this study, Balb/c and C57BL/6J mice were chosen for the study of 
carrageenan induced orofacial pain according to studies from other researchers (Mogil et 
al. 1999; Yeo et al. 2004). A von Frey hair filament was used to test the response of facial 
allodynia induced by facial carrageenan injection. 
Lambda carrageenan used to induce orofacial pain in mice in the present study is 
a mucopolysaccharide derived from the Irish sea moss. It produces inflammation, 
hypersensitivity, and some apparent spontaneous pain with a peak effect at 3-5 hours 
after injection to the rat hind paw (Tonussi and Ferreira 1992). After injection of 
carrageenan into the footpad, the cutaneous inflammation appeared within 2 hours and 
peaked at 6-8 hours. Hyperalgesia and edema were present for approximately 1 week to 
10 days. The physiological and biochemical effects are limited to the affected limb 
(Iadarola et al. 1988). Although unilateral injuries have been reported to alter sensitivity 
in remote locations including contralateral sites (Levine et al. 1985), carrageenan does 
not appear to produce changes in nociceptive threshold in the contralateral hind paw of 
the rat (Kayser and Guilbaud 1987).  
In addition, carrageenan has been found to have the ability to induce the release of 
inflammatory factors. For example, it has been shown that elevated interleukin-6 level 
appears in the circulating blood 3 hours after carrageenan injection. Carrageenan 
injection into the hind paw also induces the release of prostaglandin E2 (PGE2) from 
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isolated blood vessels of the CNS, as well as the induction of cyclooxygenase-2 (COX-2) 
and microsomal prostaglandin E synthase. It also causes nuclear translocation of signal 
transducer and activator of transcription 3 in vascular endothelial cells of the CNS (Oka 
et al. 2007).  
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3. General introduction of sphingolipids 
3.1. Structure and classification of sphingolipids 
Sphingolipids are a class of complex lipids derived from the aliphatic amino 
alcohol sphingosine. They contain an amide-linked fatty acid and a long-chain (sphingoid) 
base that are important structural components of cell membranes. Different combinations 
of sphingoid long-chain bases, fatty acids and head group moieties lead to a large number 
of sphingolipids and glycosphingolipids. The basic structure of sphingosine is shown in 
Figure 1.5. 
  
Figure 1.5 General chemical structures of sphingolipids. Different 
substituents (R) give: H— ceramide; Phosphocholine— sphingomyelins; 
Sugar— glycosphingolipids. 
There are mainly three types of sphingolipids: ceramides, sphingomyelins and 
glycosphingolipids (Figure 1.5). Ceramides consist simply of a fatty acid chain attached 
through an amide linkage to sphingosine. The fatty acid chain length of ceramide can 
vary from 2 to 28 carbons, while C16 to C24 ceramides are most abundant in mammalian 
cells. These fatty acids can be either saturated or unsaturated, and sometimes may contain 
a hydroxyl group at the C-2 position (K-hydroxy fatty acid) or on the terminal C atom 
(g-hydroxy fatty acid) (Kolesnick and Hannun 1999; Cremesti et al. 2002; Kolesnick 
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Figure 1.6 Structure of N-Acetoyl-D-erythro-Sphingosine (C2 Ceramide) (A) 
and N-Oleoyl-D-erythro-Sphingosine (C18:1 Ceramide) (B). 
Sphingomyelins have a phosphorylcholine or phosphoroethanolamine esterified to 
the hydroxy group of a ceramide. Glycosphingolipids have one or more sugar residues 
joined in a β-glycosidic linkage at the 1-hydroxyl position of ceramide. 
Glycosphingolipids consist of cerebrosides and gangliosides. Cerebrosides have a single 
glucose or galactose at the 1-hydroxy position. Gangliosides have at least three sugars, 
while one of which must be sialic acid. 
3.2. Biosynthesis of sphingolipids 
Sphingolipids are synthesized in the endoplasmic reticulum and Golgi apparatus, 
and enriched in the plasma membrane and endosomes, where they perform many of their 
functions. Transport of sphingolipids is via vesicles and monomeric transport in the 
cytosol. Sphingolipids are absent from mitochondria and the endoplasmic reticulum, but 
constitute a 20-35 molar fraction of the plasma membrane lipids (van Meer and Lisman 
2002). 
The metabolic pathways of sphingolipids are shown in Figure 1.7. It is difficult to 
determine the specific role for each sphingolipid since sphingolipid metabolites are 
interconvertible. It has been reported that the various enzymes involved in the 
metabolism of the sphingolipids are regulated by physiological stimuli such as growth 
A B
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factors and stress (Spiegel et al. 1998; Pettus et al. 2003) and might also be involved in 
some pathological conditions.  
 
Figure 1.7 Biosynthesis of sphingolipids (Colombaioni and Garcia-Gil 2004). 
The de novo pathway of ceramide synthesis can be triggered by agonist stimulations 
such as TNF-α and chemotherapeutic agents, with ceramide generated by this pathway 
having the capability of exerting biological actions (Xu et al. 1998). Condensation of 
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serine and palmitoyl CoA by serine palmitoyltransferase (SPT) initiates the pathway 
leading to ceramide generation. SPT is the first and rate-limiting enzyme in the pathway 
(Merrill et al. 1985; Merrill and Wang 1986; Perry et al. 2000). 
The sphingomyelinases are the most heavily studied enzymes in ceramide 
metabolism. Five distinct enzymes have been identified so far, based upon their pH 
optima, cellular localization, and cation dependence. They are Zn2+ dependent acid 
sphingomyelinase (ASMase), ASMase splice variant, Mg2+-independent neutral 
sphingomyelinase (NSMase), Mg2+-dependent NSMase and alkaline sphingomyelinase. 
Among these, Mg2+-independent NSMase and the lysosomal ASMase are the best studied 
for their roles in ceramide generation (Pettus et al. 2002). Sphingomyelin is hydrolyzed 
by sphingomyelinase to form ceramide and phosphocholine. ASMase is found in 
lysosomes, it has been also observed in caveoli and/or lipid rafts, which are microdomain 
of the plasma membrane that are rich in sphingomyelin (Pettus et al. 2002). ASMase can 
be activated by a large number of stimuli such as UV light, pathogens like P. aeruginosa 
and rhinoviruses, many receptors including CD95, CD28, TNF, interleukin-1 receptor 
and platelet-activating factor receptor (Gulbins and Li 2006). 
3.3. Biological effects of sphingolipids 
Sphingolipids are important structural protective components of the membrane 
lipid bilayer by forming a mechanically stable and chemically resistant outer leaflet of the 
plasma membrane. Briefly, biological membranes primarily consist of sphingolipids, 
cholesterol, and other (glycerol)phospholipids. The most prevalent component of the 
sphingolipid fraction in the cell membrane is sphingomyelin.  
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Sphingolipids are one of main important structural components of lipid raft on the 
cell membrane. Lipid rafts are a special domain in the cell membrane which can bind 
proteins, exerting various important functions like signal transduction, cytoskeletal 
organization, membrane trafficking, and pathogen entry (Simons and Ikonen 1997; 
Brown and London 1998). The theory of “lipid raft’’ hypothesis suggests that 
sphingolipids and cholesterol cluster into discrete regions of the cell membrane (Simons 
and Ikonen 1997). These sphingolipid and cholesterol rich domains are termed ‘‘lipid 
rafts’’ because they exist in a less fluid and more ordered state compared to 
glycerophospholipid-rich domains of the membrane. It is shown that cholesterol interacts 
tightly with sphingomyelin through hydrogen-bonding between the C-3 hydroxyl group 
of cholesterol and the sphingosine moiety of sphingomyelin, forming the basis for lipid 
raft (Kolesnick et al. 2000). Studies on model membranes clearly illustrate the 
phenomenon of clustering and segregation of sphingolipids, cholesterol and certain types 
of glycerophospholipids in the cell membrane, and evidence also showed the existence of 
raft-type domains in living cells (Friedrichson and Kurzchalia 1998; Varma and Mayor 
1998; Pralle et al. 2000; Dietrich et al. 2001).  
Many well known signaling proteins have been shown to either reside in or be 
transferred into or out of the rafts during the process of signal transmission. These 
signaling proteins include epidermal growth factor receptor, insulin receptor, G proteins, 
Ras, nitric oxide synthase, and TNF-α receptor (Smart et al. 1999). The localization of 
these proteins in lipid rafts, which is affected by the cytoskeleton, influences the efficacy 
and potency of both neurotransmitter receptors and transporters. In addition, the effect of 
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lipid rafts on neurotransmitter signaling has also been implicated in many neurological 
and psychiatric diseases (Allen et al. 2007). 
Besides that, sphingolipids themselves are also considered as signaling molecules 
which are involved in the control of cellular processes such as proliferation, growth, 
migration, differentiation, senescence, and apoptosis (Kolesnick and Kronke 1998; 
Spiegel et al. 1998; Hannun and Luberto 2000; Cuvillier 2002; Hannun and Obeid 2002; 
Malisan and Testi 2002). Sphingolipids can either act as first messengers binding to a 
seven-spanning G protein-coupled receptor subfamily, or as intracellular second 
messengers, capable of interacting with a multiplicity of targets. In addition, sphingolipid 
metabolites generated in cells are capable of modifying the activity of a number of 
proteins, including receptors, ion channels and enzymes as well as intracellular calcium 
levels (Colombaioni and Garcia-Gil 2004).  
3.3.1. Sphingolipids as second messengers  
It is found that sphingosine directly inhibits voltage-gated calcium channels in 
pituitary cells (Titievsky et al. 1998). It also inhibits cytosolic Ca2+-dependent NOS 
activity in rat cerebellar granule cells, probably interfering with the 
calmodulin-dependent activation of the enzyme (Viani et al. 1999). Sphingosine 
1-phosphate (S1P) and ceramide 1-phosphate (Cer1P) are able to stimulate neutral 
ceramidase in vitro (Usta et al. 2001). It is postulated that Cer1P might be involved in 
inflammatory reactions by acting on phospholipase A2 (PLA2) during glial cell injury. 
PLA2 regulates the generation of pro-inflammatory mediators through COX and 
lipoxygenase pathways. Cer1P interacts directly with cytosolic PLA2 (cPLA2), inducing 
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the activation and translocation of cPLA2 from the cytosol to the Golgi 
apparatus/perinuclear regions (Pettus et al. 2003). After ischemia or chronic injury in an 
amyotrophic lateral sclerosis transgenic model, the increased cPLA2 level is accompanied 
by elevated intracellular ceramide levels (Herr et al. 1999; Stephenson et al. 1999; Cutler 
et al. 2002). 
3.3.2. Sphingolipids affect Ca2+ mobilization in neural cells 
Sphingolipid metabolites, especially S1P, are capable of mobilizing intracellular 
calcium. It can induce Ca2+ release via inositol triphosphate (IP3), or by a direct action 
on intracellular Ca2+ stores (Ghosh et al. 1990; Meyer zu Heringdorf et al. 1998). 
Evidence has shown that TNF induces sphingomyelinase activation and transient Ca2+ 
-dependent inward currents in the dorsal root ganglia neurons. Intracellular flash 
photolysis of caged sphingosine can trigger similar currents. Likewise, extracellular S1P 
also evokes a transient rise in intracellular calcium concentration in neurons (Pollock et 
al. 2002).  
Both extracellular receptors and intracellular action of sphingolipid metabolites 
might be involved in Ca2+ mobilization. The application of lysophosphatidic acid to 
neuroblastoma cells would lead to Ca2+ mobilization, which is dependent on the 
production of S1P within cells (Young et al. 2000). In rat brain synaptosomes, 
glucosylsphingosine mobilizes calcium via IP3 receptor and sarcoplasmic/endoplasmic 
reticulum Ca2+/ATPase (Lloyd-Evans et al. 2003a; Lloyd-Evans et al. 2003b). Elevated 
levels of intracellular glucosylceramide would lead to an increase in Ca2+ release from 
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intracellular stores in the hippocampal neurons, in response to glutamate or caffeine 
(Korkotian et al. 1999).  
3.3.3. Sphingolipids affect excitability and neurotransmitter release 
Sphingolipid metabolites such as ceramide, Cer1P, sphingosine, and S1P could 
modulate the excitability and transmitter release in the CNS. It is possible that Cer1P 
plays a role in regulating neurotransmitter secretion by increasing the fusibility of the 
vesicle membranes (Bajjalieh et al. 1989). It is now known that Cer1P facilitates calcium 
entry through voltage gated calcium channels and increases the probability of opening 
these channels (Tornquist et al. 2004). On the other hand, sphingosine inhibits voltage 
gated calcium channels in the pituitary cells (Titievsky et al. 1998). Ceramide is also 
involved in the modulation of ion currents and neurotransmitter release. For instance, 
both TNF-α which could activate sphingomyelinase, and ceramide analogues decrease 
the current induced by glutamate and increase the activity of L type Ca2+ channels in 
hippocampal cells (Furukawa and Mattson 1998). 
Sphingolipids can increase neuronal excitability by decreasing K+ current. This 
leads to the depolarization of the cell membrane and the activation of voltage gated Ca2+ 
or Na+ channels. It is found that ceramide analogues block inward rectifier IK and/ or 
Ca2+-activated K+ [BKCa] in a number of cells including neuroblastoma, GH3 cells (Wu 
et al. 2001) and sensory cells (Zhang and Zhou 2002). However, effects of ceramide on IK 
might be cell-specific since it has an inhibitory effect in some cell types such as rat 
pinealocytes, oligodendrocytes, sensory neurons and neuroblastoma cells (Chik et al. 
2001; Wu et al. 2001; Zhang and Zhou 2002), but an opposite effect in cortical neurons 
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(Yu et al. 1999). So far it is still not clear whether these effects are due to ceramide or its 
metabolites, such as sphingosine or S1P.  
In addition, the excitability modulation by sphingolipids can also be done through 
regulating the target channels on the plasma membrane. The number of acetylcholine 
receptors in the plasma membrane can be decreased by 45.5% after the inhibition of 
ceramide synthase (Roccamo et al. 1999). It is found that small rafts are necessary for the 
activity of Kv1.3, which localizes to small, sphingolipid- and cholesterol-enriched rafts in 
the cell membrane. The formation of large ceramide-enriched platforms by the fusion of 
these small rafts upon the stimulation of sphingomyelinase or C16 ceramide, results in 
the clustering of this voltage dependent K channel and the inhibition of its activity (Bock 
et al. 2003). 
3.4. Biological and biophysical effects of ceramides 
A large number of intracellular targets of ceramides have been investigated. For 
example, ceramide amplifies the action of TNF-α by stimulating acid and neutral 
sphingomyelinases and by inhibiting sphingomyelin synthase (Vivekananda et al. 2001). 
In addition, it has been found that ceramide upregulates expression of cPLA2 and COX-2 
and causes a significant increase in the levels of reactive oxygen species (ROS) in 
primary hippocampal cells (Prasad et al. 2008).  
Recent studies have suggested that some effects of ceramide are mediated by its 
unique structure. Ceramide is capable of forming extensive hydrogen bonds in the 
phospholipid bilayer due to its polar headgroup, amide linkage, as well as the hydroxyl 
groups of sphingosine and the fatty acid chain. The tight interactions between ceramide 
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molecules enable the separation of ceramide-rich and -poor microdomains within the cell 
membrane. Ceramides have poor affinity for cholesterol and phospholipids in bilayers, 
and these form ceramide-enriched microdomains (Kolesnick et al. 2000). These 
properties affect the ordering of lipids in the membrane, tending to destabilize them and 
cause efflux, fusion, or budding of vesicles (Cremesti et al. 2002).  
Ceramide can mediate membrane fusion or fission by inducing a negative 
curvature because of its relatively small polar headgroup (conical shape), which favors 
vesicle formation. The changes in the membrane curvature will lead to the alteration of 
the structure of enzymes residing in the membrane, either through activating or inhibiting 
them. Recent studies have indicated that membrane fusion is critical for many cellular 
processes (Kolesnick et al. 2000). It has been demonstrated that ceramide facilitates 
vesicle aggregation and the release of vesicle contents when added to model membrane 
(Ruiz-Arguello et al. 1998; Holopainen et al. 2000; Montes et al. 2002). Besides model 
membranes, endocytic vesicles formation has been observed in ATP-depleted 
macrophages after treating with exogenous sphingomyelinase or ceramide (Zhang et al. 
1998).  
Owing to its extensive hydrogen-bonding capacity, ceramide has also been shown 
to induce pore formation in model phospholipid bilayers (Siskind and Colombini 2000). 
This might account for the postulated functions of ceramide. Ceramide is generated at the 
plasma membrane upon receptor aggregation induced by stress or agonist. This could 
lead to the local alteration in the plasma membrane permeability barrier. The changes in 
permeability and fluidity of cell membrane will lead to conformational changes in 
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membrane-associated enzymes or receptors, increase movement of proteins into or from 
rafts, induce ion fluxes, as well as alter the movement of lipids, and activating specific 
local signaling cascades. An activated receptor can also be trapped in rafts, and this 
stabilizes the interaction with the receptor ligand (Gulbins and Li 2006).  
The receptor clustering by the fusion of very small rafts to larger platform via the 
generation of ceramide leads to a high density of receptors that seems to be required for 
effective transmission of the signal into cells. Although ceramide-enriched membrane 
platforms are not part of the specific signaling cascade of the activated receptor molecule, 
these domains greatly facilitate and amplify signaling. This concept is consistent with the 
finding that ceramide-enriched membrane platforms amplify the signaling via CD95 by 
approximately 100-fold (Grassme et al. 2003). 
3.5. Sphingolipids in pain perception 
Growing evidences have indicated a role of lipids, including eicosanoids, 
diacylglycerols, lysophosphatidic acids and ceramides, in augmenting the sensitivity of 
sensory neurons and enhancing pain perception, as second messengers in signaling 
pathways or putative inflammatory mediators that activate either surface receptors or ion 
channels in sensory neurons. 
It has become more evident in recent years that sphingolipids are involved in 
nociception. In vitro studies have shown that NGF activates sphingomyelinases and 
increases the production of ceramides through p75 receptor (Dobrowsky et al. 1994; 
Brann et al. 1999). Both NGF and TNF-α alter the sensitivity of sensory neurons (Parada 
et al. 2003; Petruska and Mendell 2004). Peripheral nerve injury and inflammation lead 
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to an increase in the expression of p75 and p55 receptors in the dorsal root ganglia and 
the dorsal spinal cord (Cho et al. 1996; Ohtori et al. 2004). In isolated sensory neurons, 
C2 ceramide increases the number of evoked action potential, this phenomenon appears 
to be secondary to the augmentation of TTX-resistant Na+ channels and the inhibition of 
delayed rectifier K+ channels (Zhang et al. 2002). In a similar manner, exposing sensory 
neurons to NGF augments action-potential firing, increases the activity of TTX-resistant 
channels and inhibits K+ channel activity. These effects are attenuated by inhibiting 
neutral sphingomyelinase and blocked by pre-treatment with an antibody to the p75 
receptor to the cells (Zhang and Zhou 2002; Zhang and Nicol 2004). 
Sphingolipids are also shown to mediate peripheral sensitization directly. 
Intradermal injection of C2 ceramide or TNF-α into the dorsal hind paw of the rat results 
in hyperalgesia (Joseph and Levine 2004). TNF-α induced hyperalgesia can be blocked 
by pre-injection of a neutral sphingomyelinase inhibitor (Joseph and Levine 2004), 
suggesting that TNF-α induced hyperalgesia is mediated by the activation of the ceramide 
signaling pathway.  
 
 Chapter I  Introduction 




4. Role of free radicals in nociception 
Under normal conditions, reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are by-products of normal metabolic processes, and they function as 
physiological signaling molecules (Grisham et al. 1999). However, in pathological 
conditions, the excessive increase in ROS, such as super oxide anion (O2-), hydrogen 
peroxide (H2O2), hydroxyl radicals, and RNS, such as nitric oxide (NO) and peroxynitrite 
(ONOO-), could lead to cell death and tissue damage (Endemann and Schiffrin 2004).  
4.1. Role of nitric oxide in nociception 
NO is a molecule with 11 valence electrons, 6 from oxygen and 5 from nitrogen, 
with an unpaired electron in the last orbital, making NO a free radical (•NO). Hence, NO 
is thermodynamically unstable and tends to react with other molecules. Moreover, 
NO-mediated pathogenicity largely depends on the formation of secondary intermediates 
such as nitrites (NO2-), nitrates (NO3-) and ONOO- that are more reactive and toxic than 
NO itself (Beckman and Koppenol 1996; Radi 2004). The presence of oxidants such as 
superoxide radicals (O2-), H2O2, and transition metal centers are required for the 
formation of RNS from •NO. The concentration of these oxidants can be increased either 
by •NO itself or by the same mediators that upregulate •NO production.  
NO can be synthesized by a family of enzymes— nitric oxide synthase (NOS) 
which is present in most cells of the body. Important biological roles of NO have been 
identified in various systems. For example, NO has been shown to be an important 
neurotransmitter in the nervous system (Bredt and Snyder 1992). Four members of the 
NOS family have been identified: endothelial NOS (eNOS), neuronal NOS (nNOS), 
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inducible NOS (iNOS) and mitochondrial NOS (mtNOS). nNOS and eNOS are 
Ca2+-calmodulin-dependent enzymes expressed in mammalian cells (Mungrue et al. 
2003), and the generation of NO via these two enzymes last only a few minutes. In 
contrast, iNOS is Ca2+-calmodulin-independent and its regulation depends on de novo 
synthesis (Ebadi and Sharma 2003). iNOS is not normally expressed in the brain, but  
inflammatory mediators such as lipopolysaccharide and cytokines will induce its 
expression in microglia and astrocytes (Murphy 2000), and possibly in neurons (Heneka 
and Feinstein 2001). Once expressed, iNOS would produce high levels of NO 
continuously.  
NO and superoxide are normal signaling molecules at low concentrations, but at 
high concentrations, they are key cytotoxic molecules of innate immune defence against 
pathogens (Davies 1999; Floyd 1999; Murphy 2000; Forman and Torres 2002). They are 
also involved in the pathology of many brain diseases, including ischemia, trauma, 
inflammatory and neurodegenerative diseases, as well as aging of the brain (Floyd 1999; 
Murphy 2000; Brown and Bal-Price 2003; Zekry et al. 2003; Block et al. 2007). 
Numerous studies have indicated NO as a biological mediator in various conditions. 
However, in this thesis, the author would be placing more emphasis on the role of NO on 
nociception in the CNS. 
It is reported that intrathecal injection of NO donor causes spinally mediated 
hyperalgesia (Kitto et al. 1992), and blockage of NO synthesis eliminates hyperalgesia 
(Yamamoto et al. 1993; Meller et al. 1996) as well as formalin-induced hyperalgesia 
(Wiertelak et al. 1994). Furthermore, inhibition of spinal NO synthesis also blocks 
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NMDA-induced hyperalgesia (Kitto et al. 1992; Malmberg and Yaksh 1993) and thermal 
hyperalgesia resulting from nerve injury (Meller et al. 1992). Inhibition of spinal NO 
synthesis results in anti-nociception in rats with their paw injected with formalin (Roche 
et al. 1996). It is reported that c-fos positive neurons in superficial laminae of the caudal 
part of the spinal nucleus of the trigeminal nerve which receive the primary afferents 
from the trigeminal ganglion, are modulated by NO diffused from adjacent NOS positive 
neurons. Moreover, the NOS positive neurons are most likely local circuit neurons (Yeo 
et al. 1997; Leong et al. 2000).  
4.2. Role of superoxide in nociception  
Superoxide can be formed from activated polymorphonuclear leucocytes, 
endothelial cells and mitochondrial electron flux, and normal cellular respiration 
(McCord and Omar 1993; Lenaz 2001). The biological reactivity of superoxide is tightly 
controlled by SOD (superoxide dismutase). More superoxide will be produced during 
acute and chronic inflammations, resulting in superoxide-mediated injury (Fridovich 
1999; Muscoli et al. 2003).  
Important pro-inflammatory roles for superoxide include: (i) endothelial cell 
damage and increased microvascular permeability (Droy-Lefaix et al. 1991; Haglind et al. 
1994); (ii) up-regulation of adhesion molecules such as ICAM-1 (intercellular adhesion 
molecule 1) and P-selectin that recruit neutrophils to sites of inflammation (Salvemini et 
al. 1999; Salvemini et al. 2001); (iii) lipid peroxidation and oxidation; and (iv) DNA 
damage (Dix et al. 1996). Superoxide also activates redox-sensitive transcription factors 
including NF-κB (nuclear factor κB) and AP-1 (activator protein 1) that in turn regulate 
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genes encoding various pro-inflammatory and pro-nociceptive cytokines (Gius et al. 1999; 
Salvemini et al. 2001; Haddad and Land 2002; Matata and Galinanes 2002; McInnis et al. 
2002; Ndengele et al. 2005).  
It is reported that intraplantar injection of carrageenan to rats causes nitrotyrosine 
formation and hyperalgesia. This effect can be blocked by a SOD mimetic M40403. It is 
also shown that at the time of peak hyperalgesia, endogenous manganese SOD is nitrated 
and subsequently deactivated at the spinal cord, hence lose its capacity to remove 
superoxide (Wang et al. 2004). It is suggested that ROS mediates the development and 
the maintenance of capsaicin-induced-hyperalgesia in mice, mainly through central 
sensitization. And the elevation of spinal ROS is most likely due to increased production 
of mitochondrial superoxide in the dorsal horn neurons (Schwartz et al. 2008). 
Recent results have demonstrated that the removal of superoxide and 
superoxide-derivatives is effective in inhibiting peripheral and central sensitization 
associated with severe pain. Superoxide scavengers have been shown to be effective in 
reducing acute inflammatory pain (Wang et al. 2004; Nishiyama and Ogawa 2005), 
glutamate-induced hyperalgesia (Muscoli et al. 2004), neuropathic pain (Tal 1996; 
Chuang et al. 2001; Kim et al. 2004; Kim et al. 2006; Naik et al. 2006; Park et al. 2006), 
trigeminal pain and temporomandibular joint dysfunction (Viggiano et al. 2005).  
4.3. Role of peroxynitrite in nociception  
Peroxynitrite can be formed through the interaction between superoxide and nitric 
oxide in situ (Beckman et al. 1990) (Figure 1.8). Removal of peroxynitrite results in 
cytoprotective and anti-inflammatory effects (Misko et al. 1998; Salvemini et al. 1998a; 
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Salvemini et al. 1998b). The most important property of peroxynitrite in inflammation is 
its ability to nitrate protein tyrosine groups, resulting in modification of the functional 
activity of key proteins (Fries et al. 2003; Muscoli et al. 2003; Radi 2004; Wang et al. 
2004) (Figure 1.8). Another mechanism of nitration is via H2O2 and myeloperoxidase 
(Eiserich et al. 1998). Nitration and inactivation of manganese-complexed SOD also play 
a role in the development of peripheral and central pain sensitization (Muscoli et al. 2004; 
Wang et al. 2004).  
 
Figure 1.8 Peroxynitrite-mediated tyrosine nitration plays a key role in 
inflammation and pain. Nitration can be focused on specific tyrosine residues 
on proteins, resulting in loss (↓) or gain (↑) of protein function (Cassina et al. 
2000; Salvemini et al. 2006). 
Protein nitration of specific tyrosine residues results in structural modification, 
and loss or gain of protein function (Cassina et al. 2000; Balafanova et al. 2002; Vadseth 
et al. 2004). For example, nitration of cytochrome c, voltage-dependent ion channel, and 
ATPase disrupts mitochondrial metabolism, and this in turn triggers apoptotic signaling 
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of cell death (Radi et al. 2002; Turko and Murad 2003). The enhanced peroxidative 
activity of nitrated cytochrome c may further contribute to oxidative damage (Cassina et 
al. 2000; Radi et al. 2002). In addition, nitration of glutamate transporters by 
peroxynitrite inhibits their ability to transport glutamate from the synaptic cleft to the 
neurons, where it is then metabolized to non-toxic glutamine by glutamine synthase 
(Kennedy et al. 1974). The latter can also be nitrated by peroxynitrite and lose its 
enzymatic activity (Minana et al. 1997; Gorg et al. 2005). As a consequence, the 
accumulated glutamate in the synaptic cleft will lead to neurotoxicity. Peroxynitrite can 
nitrate tyrosine residues present on the NMDA receptor subunits, leading to constant 
potentiation of synaptic currents, calcium influx and ultimately neuronal excitotoxicity 
(Mishra and Delivoria-Papadopoulos 1999; Zanelli et al. 2000; 2002).  
4.4. Interaction between sphingolipids and ROS/RNS 
 It has been reported that ROS/ RNS are involved in sphingolipid metabolism. For 
example, sphingomyelinases and ceramidase activities are affected by the depletion of 
cellular reduced glutathione due to increased ROS and RNS levels (Huwiler et al. 1999; 
Mansat-de Mas et al. 1999; De Nadai et al. 2000; Qiu et al. 2003). On the other hand, 
sphingolipids including ceramide, sphingosine, and S1P can regulate cellular redox 
homeostasis through the regulation of NADPH oxidase (Garcia-Ruiz et al. 1997; Zhang 
et al. 2003), mitochondrial integrity (Garcia-Ruiz et al. 1997), NOS (Viani et al. 2001; 
Won et al. 2004), and antioxidant enzymes (Macmillan-Crow and Cruthirds 2001; Iwai et 
al. 2003).  
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4.4.1. Regulation of sphingolipid metabolism by oxidative stress 
 Exogenous or endogenous NO has been shown to inhibit TNF-α-mediated 
apoptosis via inhibiting acid sphingomyelinase (ASMase) and decreasing ceramide 
generation (De Nadai et al. 2000; Bulotta et al. 2001). NO also increases the level of 
cyclic guanosine monophosphate (cGMP) and activates cGMP-dependent protein kinase 
which is thought to inhibit ASMase (Barsacchi et al. 2002; Falcone et al. 2004). It is also 
reported that sodium nitroprusside, a NO donor, increases sphingomyelin hydrolysis and 
ceramide generation through the activation of neutral sphingomyelinase (NSMase) 
(Takeda et al. 1999). 
4.4.2. Regulation of redox potential by sphingolipids 
  Increasing evidences suggest that certain sphingolipids such as ceramides or its 
glycosyl derivates, are able to induce cellular oxidative stress via various mechanisms. 
Ceramide and sphingosine are potential activators for mitochondrial dysfunction, leading 
to an increased production of O2−, abnormal electron transfer, mitochondrial lipid 
peroxidation, opening permeability transition pore, and cytochrome c release. Ceramide 
can activate the gene expression of redox enzymes (i.e., iNOS and manganese-complexed 
SOD) through receptor clustering, recruitment of signaling enzymes, and activation of 
certain protein kinases (i.e., PKCζ and kinase suppressor of Ras). The ceramide-activated 
signaling cascades, together with its derivatives such as glucosyl-ceramide and 
lactosyl-ceramide, may be involved in the regulation of NADPH oxidase activity. 
Ceramide is also able to inhibit the action of eNOS through NADPH-mediated O2− 
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Lipid mediators including phospholipids and lysophospholipids play important 
roles in the normal physiology of the brain. However, relatively little is known about 
whether CNS ceramides could also play a role in orofacial allodynia. The present study 
was therefore carried out to evaluate possible effects of CNS sphingomyelinase and/or 
ceramides in a mouse facial carrageenan injection model of orofacial pain. 
Previous study showed that increased ceramides were found in rat hippocampus 
after kainate-induced excitotoxic injury (Guan et al. 2006). Such changes could be due to 
increased neuronal excitation caused by kainite injection. Similar increases in neuronal 
excitation could also occur in the CNS during hyperalgesia (Gibbs et al. 2006). It was 
postulated that CNS ceramides — member of sphingolipid family— might also play a 
role in carrageenan induced facial allodynia. The first part of study was then carried out 
to examine whether the inhibition of CNS ceramide formation was effective in reducing 
orofacial allodynia after facial carrageenan injection. It was found that acid 
sphingomyelinase inhibitor D609 was effective in reducing allodynia.  
Electrophysiological study of the role of ceramides in inducing exocytosis was 
then performed to provide possible mechanistic explanation for the effects of ceramides 
on orofacial allodynia. Various ceramide species were examined for their ability to 
induce membrane capacitance changes and whether ceramides could reduce the number 
of subplasmalemmal vesicles in PC12 cells.  
Since D609 is also a free radical scavenger besides being an ASMase inhibitor, a 
possible role of CNS free radicals in facial allodynia was further examined using the spin 
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trap/ free radical scavenger PBN. It was found that intracerebroventricular (ICV) 
injection of PBN was effective in reducing orofacial allodynia after facial carrageenan 
injection.  
Previous study showed an increase in microglial activity after formalin-induced 
facial allodynia (Yeo et al. 2001). Since microglia produces NO, which could combine 
with superoxide to form peroxynitrite, it was postulated that CNS peroxynitrite could 
play a role in facial allodynia. The last part of study was then carried out using ICV 
injections of ONOO- donor and scavenger to elucidate the effects of CNS peroxynitrite 

































Chapter 3.1 Possible Effects of CNS Ceramides on Allodynia 














An increasing number of lipids, including eicosanoids, diacylglycerols, 
lysophosphatidic acids and sphingolipids have been implicated in increasing the 
sensitivity of sensory neurons and enhancing pain perception. Many of these lipids are 
second messengers in signaling pathways of sensory neurons (Colombaioni and 
Garcia-Gil 2004; Park and Vasko 2005). For example, one class of lipid mediators, the 
acylethanolamides, inhibits pain response, while the others appear to enhance pain 
sensitivity (Malan and Porreca 2005). Among these lipids, ceramides have been recently 
found to be important signaling molecules in diverse cellular processes.  
Ceramides are generated via hydrolysis of sphingomyelin by sphingomyelinases 
or de novo synthesis through enzymes such as serine palmitoyltransferase (SPT) or 
ceramide synthase (Kolesnick and Hannun 1999). Ceramide can be phosphorylated by 
ceramide kinase to Cer1P, or metabolized by ceramidase to sphingosine, which can then 
be phosphorylated by sphingosine kinase to S1P. All the above compounds can affect cell 
signaling. Exposure of cultured rat dorsal root ganglion neurons to C2 ceramide, or 
intracellular perfusion with bacterial sphingomyelinase produced a 3-4 folds increase in 
the number of action potentials (Zhang et al. 2002). This might be due to the 
enhancement of a tetrodotoxin-resistant sodium current and/or reduction in outward 
potassium current, by ceramide or S1P, in these neurons (Zhang et al. 2006). S1P also 
contributes to depolarization induced neurotransmitter release in PC12 cells (Alemany et 
al. 2001). In addition, enhancement of calcium entry through voltage dependent calcium 
channels has been reported, after the addition of ceramide 1-phosphate (Cer1P) 
 






(Tornquist et al. 2004). In humans, mutations in SPTLC1 (Serine palmitoyltransferase, 
long chain base subunit 1) which encodes serine palmitoyltransferase (SPT) have been 
detected in patients with hereditary sensory neuropathy type I (Dawkins et al. 2001). 
These observations provide direct evidence for a connection between altered ceramide 
metabolism and somatosensation. 
An increased level of ceramide species such as C18:0, C24:1 and C24:0 ceramide 
have been found by non-targeted lipid profiling (lipidomic analysis) of rat hippocampus 
after kainate-induced excitotoxic injury (Guan et al. 2006). Treatment of hippocampal 
slice cultures with SPT inhibitor myriocin or L-cycloserine resulted in modulation of the 
ceramide production (He et al. 2007). These results suggest that besides breakdown of 
sphingomyelin, some of increased ceramide could have been produced as a result of de 
novo synthesis. Such changes could be due to increased neuronal excitation after 
injection of kainate. Similar increases in neuronal excitation could also occur in the CNS 
during hyperalgesia (Gibbs et al. 2006), although at present little is known about the role 
of ceramide in these conditions.  
The present study was therefore carried out, by reducing the CNS ceramide 
production through direct injection of inhibitors to sphingomyelinases or SPT into the 
third ventricle of the brain, to elucidate a possible role of CNS ceramides in a mouse 
model of orofacial pain induced by facial carrageenan injection (Yeo et al. 2004). 
 






2. Materials and methods 
2.1. Behavioral experiment 
2.1.1. Animal groups and chemicals  
Table 3.1 Treatment groups of Balb/c mice. 
 
Treatment Enzyme Solvent Concentration n 
W
ith facial carrageenan injection 
D609 ASMase and PC-PLC Saline 
2 mM 7 
0.2 mM 7 
0.02 mM 7 
PtdIns3,5P2 
 ASMase Saline 
2 mM 7 
0.2 mM 7 
0.02 mM 7 
GW4869 NSMase 100% DMSO 
2 mM 4 
0.2 mM 4 
0.02 mM 4 
L-cycloserine SPT Saline 
2 mM 5 
0.2 mM 4 
0.02 mM 4 
Myriocin SPT Saline 
2 mM 5 
0.2 mM 4 
0.02 mM 4 
Saline Vehicle control   8 
100%DMSO Vehicle control   4 





Saline Vehicle control   4 
100%DMSO Vehicle control   4 
D609 ASMase Saline 2 mM 4 
GW4869 NSMase 100% DMSO 2 mM 4 
L-cycloserine SPT Saline 2 mM 4 
Summary   23 groups 118 mice 
 






Altogether 118 adult male Balb/C mice, about 6-8 weeks of age and weighing 
approximately 20-30 g each were purchased from the Laboratory Animals Centre, 
Sembawang, Singapore. All measures were taken to minimize pain or discomfort, and 
experiments were conducted in accordance with international standards on animal 
welfare and compliant with standards defined by the European Communities Council 
Directive of 24 November 1986 (86/609/EEC). These mice were randomly divided into 
23 groups, with 4 to 8 mice per group. Eighteen groups were used to study the effects of 
various inhibitors on facial carrageenan induced allodynia. Five groups were used to test 
effects of inhibitors on normal somatosensation (Table 3.1).  
Chemicals used for behavioral assessment are shown in Table 3.1. O-Tricyclo 
[5.2.1.02,6] dec-9-yl dithiocarbonate potassium salt (D609), GW4869, L-cycloserine, and 
myriocin were purchased from Sigma, St Louis, USA. D-myo-phosphatidylinositol 
3,5-bisphosphate (PtdIns3,5P2) was from Echelon, Salt Lake City, USA. 
The enzyme inhibitors used in the present study are thought to have fairly specific 
actions, except acid sphingomyelinase (ASMase) inhibitors. Neutral sphingomyelinase 
(NSMase) inhibitor GW4869 is a cell-permeable, symmetrical dihydroimidazolo-amide 
compound that acts as a potent, specific, non-competitive inhibitor of NSMase (Luberto 
et al. 2002). L-cycloserine and myriocin are commonly used inhibitors for serine 
palmitoyltransferase (SPT) (Holleran et al. 1990; Miyake et al. 1995). 
 Thus far, no specific ASMase inhibitor has been found. Commercially available 
ASMase inhibitors such as D609, imipramine, desipramine, PtdIns3,5P2 are not specific 
 






for the ASMase, imipramine and desipramine are anti-depression drugs, and PtdIns3,5P2 
is a second messenger involved in a number of cellular signaling processes. D609 is a 
xanthogenate derivative with a variety of biological effects, including antiviral, 
antitumor, and anti-inflammatory activities (Zhou et al. 2001). It inhibits 
phosphatidylcholine-specific phospholipase C (PC-PLC) (Tschaikowsky et al. 1994), as 
well as ASMase activities (Simarro et al. 1999; Koishi et al. 2002; Strle et al. 2004). It is 
also a potent antioxidant, with the ability to scavenge intracellular reduced glutathione 
and inhibit intracellular ROS accumulation in cells (Zhou et al. 2001; Lauderback et al. 
2003; Sultana et al. 2004). The median inhibition concentration (IC50) of D609 was 
50~100 μg/ml in vitro (Kahle et al. 1998; Luberto and Hannun 1998). The concentrations 
of D609 injected were thus 1/10, 1 and 10 times of the IC50 (50 μg/ml). D609 has a 
relatively long half-life of 1.5 days (Kahle et al. 1998). PtdIns3,5P2 and a similar analog 
PtdIns3,4,5P3 have been shown to be inhibitor of ASMase (Kolzer et al. 2003; Testai et 
al. 2004). The half life of PtdIns3,5P2 is about 2-5 hours (Brearley and Hanke 1995), 
however, its IC50 in vivo or in vitro has not been investigated so far.  
2.1.2. Behavioral assessment  
Mice were assessed for behavioral responses to von Frey hair (Touch-Test 
Sensory Evaluator, North Coast Medical, Morgan Hill, USA) stimulation applied to the 
right maxillary area at 1 day before injections, 6 hours, 1 day and 3 days after 
intracerebroventricular (ICV) injection and facial carrageenan injection. The von Frey 
hair filament delivering ~ 1 g force (4.08 log units) was used. A coding system was used 
 






to blind the investigator to the nature of the surgical procedures performed on individual 
animals. 
Chemicals administered via ICV injections did not produce any gross 
abnormalities in behavior or locomotion after mice woke up from anesthesia. The time 
point of 6 hours after injection was chosen because at that time, mice would be fully 
awake, and moved freely without obvious motor deficits. In addition, pilot observations 
showed that the number of responses to von Frey hair stimulation peaked at 3 to 4 days 
after facial carrageenan injection, hence, testing of effects of different chemicals was 
extended up to that time, i.e., 3 days after facial carrageenan injection. 
The mice were tested individually in a deep rectangular stainless steel tank (60 × 
40 × 25 cm3). Mice were habituated to the movements of von Frey hair and the 
experimental environment for 5 to 10 min before testing. The mechanical stimulations 
were administered only when the mice were in a non-locomotion state, with four paws 
placed on the ground, neither moving nor freezing, but exhibiting sniffing behavior. A 
new stimulus was applied at least 30 seconds after the previous stimulation (Vos et al. 
1994). Directed facial grooming, i.e. uninterrupted series of face-wash strokes directed to 
the stimulated maxillary area, was used as an indicator of unilateral facial pain in freely 
moving mice (Vos et al. 1998).  
Twenty probes were delivered to each mouse to obtain sufficient number of 
responses to reduce variability among individual animals in each group. The total number 
of face wash strokes after the delivery of 20 probes was noted for each mouse, and the 
mean and standard deviation of each group were calculated. Possible differences between 
 






the means were elucidated using one-way ANOVA with Bonferroni's multiple 
comparison post hoc test (SPSS 12.0 for Windows software).  
2.1.3. Intracerebroventricular injection  
Intracerebroventricular (ICV) injections were carried out as previously described 
(Yeo et al. 2004). The anesthesia used in the present study was a mixture of 7.5% 
ketamine and 10% medetomidine, administered via intraperitoneal (IP) injection. Each 
mouse was injected with a volume of 0.1 ml per 10 g body weight.  
Mice were deeply anaesthetized, and the operation site was prepared by clipping 
the fur and swapping with alcohol. Each mouse was then fixed on a stereotaxic apparatus. 
The cranial was exposed via a midline incision. A small bur hole (approximately 2 mm 
diameter) was then made on the skull around the area of the third ventricle, and 5 μl of 
solution was injected slowly in 5 minutes. The coordinates were: 0.7 mm caudal to 
bregma, 1.0 mm lateral to the midline, 3.0 mm from the surface of the cerebral cortex. 
The wound was then closed with sutures. 
2.1.4. Facial carrageenan injection 
λ-carrageenan (Sigma, St Louis, USA) was suspended in sterilized saline at a 
concentration of 40 mg/ml. Fifty microliter of carrageenan suspension was 
subcutaneously injected into the right maxilla area of the mice to study the effects of 
these inhibitors on allodynia (Table 3.1). 
 






2.2. ASMase activity assay and PC-PLC activity assay 
2.2.1. Animals and tissue harvesting 
Twenty-one Balb/c mice, randomly divided to 3 equal groups, were used to test 
ASMase and PC-PLC activity changes in brain after facial carrageenan injection and ICV 
injection of D609. Seven mice received ICV injection of 5 µl of 2 mM D609 and right 
facial carrageenan injection, seven received ICV injection of 5 µl of saline plus right 
facial carrageenan injection, the last seven were without any treatment (untreated 
control). ICV injection and facial carrageenan injection were carried out as previously 
described (chapter 3.1, page 51). 
Mice were deeply anesthetized and sacrificed by decapitation 3 days after ICV 
and facial injections. The left and right halves of the brain stem (containing the trigeminal 
nucleus), the left and right thalamus (containing the ventral posterior nucleus of the 
thalamus), and the left and right primary somatosensory cortex (SI) (barrel field) were 
dissected out by referring to a mouse atlas, to roughly scan the ASMase and 
phosphatidylcholine-specific phospholipase C (PC-PLC) activities in different parts of 
brain. 
2.2.2. Enzyme activity assay 
Tissue samples were homogenized in 0.25% Triton X-100, the homogenate was 
centrifuged (10,000g for 5 min at 4 °C) and protein concentrations of supernatant was 
determined by Bio-Rad protein assay (Bio-Rad, California, USA.) (Bradford 1976). The 
remaining supernatant was used for enzyme activity assay using commercial kits— 
 






Amplex red sphingomyelinase assay kit and Amplex red phosphatidylcholine-specific 
phospholipase C assay kit (both from Molecular Probes, Eugene, Oregon, USA).  
Sphingomyelinase hydrolyzes sphingomyelin to ceramide and phosphocholine. 
PC-PLC converts the phosphatidylcholine (lecithin) substrate to form phosphocholine 
and diacylglycerol. Phosphocholine is then hydrolyzed by alkaline phosphatase to 
phosphate and choline, which is oxidized by choline oxidase to betaine and H2O2. H2O2 
then reacts with 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent) to produce 
highly fluorescent resorufin, which is detected by fluorescence emission at 590 nm.  
The ASMase activity assay was carried out by following the product manual from 
the company. Each sample was diluted in 50 mM sodium acetate (pH 5.0) and sodium 
acetate was used as a negative control. A volume of 100 μl was used for each reaction. 10 
μl of 5 mM sphingomyelin was added to each sample or negative control and incubated 
at 37 °C for one hour. 100 μl of 0.4 U/ml sphingomyelinase and 10 μM H2O2 were used 
as positive controls. After that, 100 μl of the samples and controls were transferred into 
separate wells of a 96 well fluorescence microplate. Ten microliter of the 5 mM 
sphingomyelin solution was added to each positive control. Reactions were began by 
adding 100 μl of the working solution [100 μM Amplex® Red reagent containing 2 U/ml 
HRP, 0.2 U/ml choline oxidase and 8 U/ml alkaline phosphatase in 100 mM Tris-HCl 
(pH 8.0)] to each microplate well containing the samples and controls. The microplate 
was then incubated for 30 minutes at 37 °C, protected from light.  
The PC-PLC activity assay was carried out by following the product manual from 
the company. Each sample was diluted in reaction buffer (50 mM Tris-HCl, pH 7.4, 140 
 






mM NaCl, 10 mM dimethylglutarate, 2 mM CaCl2). PC-PLC (0.1 U/ml) solution and 
H2O2 (10 μM) in reaction buffer were positive controls. Reaction buffer without PC-PLC 
was used as a negative control. A volume of 100 μl was used for each reaction. 100 μl of 
the diluted samples and controls were pipetted into separate wells of 96 well fluorescence 
microplate. reactions were began by adding 100 μl of working solution (400 μM 
Amplex® Red reagent containing 2 U/ml HRP, 8 U/ml alkaline phosphatase, 0.2 U/ml 
choline oxidase and 1 mM lecithin in reaction buffer) to each microplate well containing 
the samples and controls. The microplate was then incubated for 30 minutes at 37 °C, 
protected from light.  
Fluorescence reading was measured using a fluorescence microplate reader 
(Tecan, Grödig/Salzburg, Austria). The fluorescence was excitated at 530 nm and 
emission was detected at 590 nm. Each measurement was corrected for background 
fluorescence by subtracting the values derived from the negative control. Each assay was 
performed in duplicate and results were normalized by protein concentration. Possible 
differences between the means were elucidated using one way ANOVA test with 
Bonferroni’s multiple comparison post-hoc test (SPSS 12.0 for Windows software).  
2.3. The effect of free radical spin trap phenyl-N-tert-butylnitrone (PBN) on facial 
allodynia 
PBN is one of the most commonly used spin traps (Lee at al. 2007). The 
biological half-life of PBN in rats is 134 min (Chen et al. 1990; Lee et al. 2007). PBN 
was freshly prepared before injection and dissolved in saline at a concentration of 40 
mg/ml. This dose of PBN was modified from previous study (Lee et al. 2007).  
 






Fourteen adult male Balb/c mice were used to study the effect of PBN (Sigma, St 
Louis, USA) in carrageenan injected mice. Mice were randomly divided into two groups 
with seven each. The mice were assessed for behavioral responses to von Frey hair 
stimulation before treatments, and 3 days after facial carrageenan injection. At the third 
day after facial carrageenan injection, mice received ICV injection of 5 μl of PBN or 
saline (vehicle control) after the behavior test, 6 hours later when the mice were fully 
awake and did not produce any gross abnormalities in behavior or locomotion, mice 
received the behavior assessment again. Mice were also received the behavior assessment 
1 day after ICV injection of PBN or saline. The method of behavior test, ICV injection 
and facial carrageenan injection were the same as previously described (chapter 3.1, page 
49-51). 
2.4. Intracellular H2O2 production in PC12 cells induced by ceramides 
2.4.1. Cells and chemicals 
 PC12 cells (pheochromocytoma cells) were cultured in RPMI Medium 
supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Gibco, 
Invitrogen, Carlsbad, CA). The cells were plated in 35 mm Petri dishes, and maintained 
in an incubator at 37 0C, 100% humidity, with 95% air and 5% CO2.  
 






Table 3.2 Chemicals used in H2O2 assay. Abbreviation: KRPG: Krebs-Ringer 
phosphate buffer. 
 
2.4.2. H2O2 assay in PC12 cells 
 First, effects of different concentration of C18 ceramide on the H2O2 production 
in PC12 cells were tested, i.e., 10 μM, 50 μM, 100 μM (final concentration). C18 
ceramide level was found to be increased in rat hippocampus after kainate-induced 
excitotoxic injury using the method of non-targeted lipid profiling (lipidomic analysis) 
(Guan et al. 2006).  It was observed that 100 μM C18 ceramide was the one which 
significantly increased the production of H2O2, C18 ceramide with this concentration was 
then chosen to further investigate the possible underlying mechanisms. L-type calcium 
channel inhibitor nifedipine, mitochondria permeability transition pore blockers 
bongkrekic acid and cyclosporine A, free radical scavengers D609 and PBN were used to 
test whether they can influence the effect of C18 ceramide on H2O2 production (Table 
3.2). The vehicle of ceramides, DMSO, was used as negative control. Untreated PC12 
cells were also used as another negative control. 
Chemicals Source Final Concentration Solvent 
C18 ceramide Avanti Polar Lipids, Alabaster, USA 
10 μM, 50 μM, 
100 μM DMSO 
Nifedipine Sigma, St Louis, USA 10 μM DMSO 
Bongkrekic acid (BKA) Sigma, St Louis, USA 1 μM KRPG 
Cyclosporine A (CsA) Sigma, St Louis, USA 1 μM KRPG 
D609 Sigma, St Louis, USA 50 μM KRPG 
phenyl-N-tert-butylnitrone 
(PBN) Sigma, St Louis, USA 1 mM KRPG 
 






 The H2O2 assay in PC12 cells was carried out using a commercial available kit-- 
Amplex® Red Hydrogen Peroxide/ Peroxidase Assay kit (Molecular Probes, Eugene, 
Oregon USA). The method was modified from the product manual provided by the 
company and is as follows: The reaction mixture contained 50 μM Amplex Red reagent 
and 0.1 U/ml HRP in KRPG (145 mM NaCl, 5.7 mM Na3PO4, 4.86 mM KCl, 0.54 mM 
CaCl2, 1.22 mM MgSO4, 5.5 mM glucose, pH 7.35). One hundred microliter of the 
reaction mixture was pipetted into each microplate well (Greiner 96 well plate, black for 
fluorescence) and pre-warmed at 37 °C for 10 minutes. Ten microliter of chemical 
solution/mixture was then added into each microplate well. Each treatment was repeated 
several times (no less than four times). The final concentrations of each chemical were 
listed in Table 3.2. For non-treatment negative control, only 10 μl KRPG was added to 
the microplate well. 
Cell density was counted using a hemacytometer and trypan blue, and a cell 
suspension with a density of 1.5 × 106 cells/ml in Krebs-Ringer phosphate buffer (KRPG) 
was obtained. The reaction was started by adding 10 µl of cells suspension to each 
microplate well containing chemical solution or 10 μl KRPG, i.e. 1.5 × 104 cells in each 
microplate well with a final volume of 120 µl in each well. For background control, only 
20 μl of KRPG was added (without PC12 cells). The microplate was incubated at 37 °C 
for three hours. The absolute fluorescence reading was then recorded using a 
fluorescence microplate reader (Tecan, Grödig / Salzburg, Austria) equipped for 
excitation at 530 nm and emission detection at 590 nm, and normalized by subtracting the 
value derived from the background control. Possible differences between the means were 
 






elucidated using one way ANOVA test with Bonferroni’s multiple comparison post-hoc 
test (SPSS 12.0 for Windows software).  
3. Results 
3.1. Behavioral experiment 
3.1.1. Effects of vehicle controls on facial carrageenan injected mice 
 Mice showed significantly increased face wash strokes at 1 day and 3 days after 
facial carrageenan injection, or facial carrageenan plus ICV saline injection, compared to 
before injection and 6 hours after injection (Figure 3.1A, B, Table 3.3), indicating 
allodynia.  
Mice injected with 100% DMSO plus carrageenan showed significantly increased 
face wash strokes at 3 days after injections, compared to the same group before 










   
Figure 3.1 Effect of vehicle controls on facial allodynia in mice. A: Effect of 
facial carrageenan injection. B: Effect of ICV saline plus facial carrageenan 
injection. C: Effect of ICV injection of 100% DMSO plus facial carrageenan 
injection. All control groups showed significant allodynic effect at 3 days after 
injection, compared with before injection and 6 hours after injections. Data 
was shown in Mean ± SD. * indicates P<0.05; ** indicates P<0.01.  
 
 
Table 3.3 Number of face wash strokes in control groups. Mean ± SD of the 
number of face wash strokes in each group at different time point is presented.  
Treatment n Before Injection 6H 1D 3D 
Carrageenan alone 6 4.5 ± 2.8 2.2 ± 2.0 14.2 ± 3.3 13.2 ± 4.1 
Saline + carrageenan 8 3.0 ± 2.0 5.1 ± 2.8 11.2 ± 5.4 17.5 ± 5.3 








































































3.1.2. Effects of ASMase inhibitors on carrageenan injected mice  
 Mice injected with 2 mM D609 plus carrageenan, showed significantly fewer face 
wash strokes, compared to mice injected with saline and the two lower doses of D609, at 
1 day and 3 day post-injection (Figure 3.2, Table 3.4). 
Mice injected with 2 mM PtdIns3,5P2 showed significantly fewer face wash 
strokes at 3 day after injections, compared to those injected with saline plus carrageenan 
(Figure 3.3, Table 3.5). 
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0.2 mM D609 + C







Figure 3.2 Effect of ASMase inhibitor D609 on facial allodynia in mice. Mice 
injected with 2 mM D609 showed significantly reduced allodynic effect at 1 
day and 3 days after injection, compared with saline injected mice, and the 
two lower doses of D609 injected mice. Abbreviation: C: carrageenan. * 
indicates P<0.05; ** indicates P<0.01.  
 
 
Table 3.4 Number of face wash strokes after D609 plus carrageenan injection. 
Mean ± SD of each group is shown. Abbreviation: C: carrageenan. ^ indicates 
significant difference compared with before injection within the same 
treatment group (^: P<0.05; ^^: P<0.01). # indicates significant difference 
compared with 6 hours after injection within the same treatment group (#: 
P<0.05; ##: P<0.01). & indicates significant difference compared with 1 day 
after injection within the same treatment group (&: P<0.05). 
 
   
Treatment n Before Injection 6H 1D 3D 
Saline + C 8 3.0 ± 2.0  5.1 ± 2.8  11.2 ± 5.4^^# # 17.5 ± 5.3^^##& 
0.02 mM D609 + C 7 4.0 ± 1.8 6.4 ± 4.8 8.6 ±4.6 10.4 ± 4.5^ 
0.2 mM D609 + C 7 4.4 ± 1.5  4.8 ± 4.2 9.7 ± 4.0^ 11.8 ± 2.8^^# # 
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Figure 3.3 Effect of ASMase inhibitor PtdIns3,5P2 on facial allodynia in mice. 
Mice injected with 2 mM PtdIns3,5P2 showed significantly reduced allodynic 
effect at 3 days after injection, compared with saline injected mice. 
Abbreviation: C: carrageenan. * indicates P<0.05; ** indicates P<0.01. 
 
 
Table 3.5 Number of face wash strokes after PtdIns3,5P2 plus carrageenan 
injection. Mean ± SD of each group is shown here. Abbreviation: C: 
carrageenan. ^ indicates significant difference compared with before injection 
within the same treatment group (^: P<0.05; ^^: P<0.01). # indicates 
significant difference compared with 6 hours after injection within the same 
treatment group (#: P<0.05; ##: P<0.01). & indicates significant difference 
compared with 1 day after injection within the same treatment group (&: 
P<0.05). 
Treatment n Before Injection 6H 1D 3D 
Saline + C 8 3.0 ± 2.0
  5.1 ± 2.8  11.2 ± 5.4^^# # 17.5 ± 5.3^^##& 
0.02 mM PtdIns3,5P2 + C 7 4.0 ± 1.7 5.7 ± 3.5  15 ± 2.8^^# # 16.1 ± 4.3^^## 
0.2 mM PtdIns3,5P2 + C 7 5.3 ± 1.6 3.6 ± 3.0  10 ± 3.5# 13 ± 5.2^## 










3.1.3. Effect of NSMase inhibitor on carrageenan injected mice 
Mice injected with 2 mM and 0.2 mM GW4869 showed significantly reduced 
allodynia compared with DMSO injected mice at 3 days after injection (Figure 3.4, Table 
3.6). 
3.1.4. Effect of SPT inhibitor on carrageenan injected mice 
 Mice injected with 2 mM and 0.2 mM L-cycloserine showed significantly reduced 
allodynia compared with saline injected mice at 3 days after injection (Figure 3.5A, Table 
3.7). 
  Mice injected with myriocin (all 3 doses i.e., 0.02 mM, 0.2 mM and 2 mM) 
showed significantly reduced allodynia compared with DMSO injected mice at 3 days 
after injection (Figure 3.5B, Table 3.7). 
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Figure 3.4 Effect of NSMase inhibitor GW4869 on facial allodynia in mice. 
Mice injected with 2 mM and 0.2 mM GW4869 showed significantly reduced 
allodynia compared with DMSO injected mice at 3 days after injection. 
Abbreviation: C: carrageenan. * indicates P<0.05; ** indicates P<0.01. 
 
 
Table 3.6 Number of face wash strokes after GW4869 plus carrageenan 
injection. Mean ± SD of each group is shown here. Abbreviation: C: 
carrageenan. ^ indicates significant difference compared with before injection 
within the same treatment group (^: P<0.05; ^^: P<0.01). # indicates 
significant difference compared with 6 hours after injection within the same 
treatment group (#: P<0.05; ##: P<0.01). & indicates significant difference 
compared with 1 day after injection within the same treatment group (&: 
P<0.05). 
Treatment n Before Injection 6H 1D 3D 
100% DMSO + C 4 1.5 ± 1.3 6.5 ± 4.9 13 ± 6.3 26.2 ± 6.5^^##& 
0.02 mM GW4869 + C 4 2.5 ± 0.6 7.5 ± 1.7 11.2 ± 8.0 20.7 ± 5.5^^# 
0.2 mM GW4869 + C 4 3.5 ± 2.4 5.2 ± 3.8 10.0 ± 3.7 9.7 ± 3.2 






































Figure 3.5 Effects of SPT inhibitor L-cycloserine and myriocin on facial 
allodynia in mice. A: Mice injected with 2 mM and 0.2 mM L-cycloserine 
showed significantly reduced allodynia compared with saline injected mice at 
3 days after injection. B: Mice injected with all 3 doses of myriocin showed 
significantly reduced allodynia compared with DMSO injected mice at 3 
days after injection. Abbreviations: LCS: L-cycloserine. C: carrageenan. * 
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Treatment n Before Injection 6H 1D 3D 
Saline + C 8 3.0 ± 2.0 5.1 ± 2.8 11.2 ± 5.4^^# # 17.5 ± 5.3^^##& 
0.02 mM L-cycloserine + C 4 0.4 ± 0.9 2.6 ± 1.1 7.6 ± 6.5^ 12.0 ± 2.0^^## 
0.2 mM L-cycloserine + C 4 2.0 ± 1.6 1.8 ± 1.2 9.8 ± 3.1^^## 9.2 ± 2.2^^## 
2 mM L-cycloserine + C 5 1.6 ± 2.3 3.2 ± 3.3 6.4 ± 5.2 8.6 ± 5.6 
100% DMSO + C 4 1.5 ± 1.3 6.5 ± 4.9 13 ± 6.3 26.2 ± 6.5^^##& 
0.02 mM myriocin + C 4 1.0 ± 1.4 1.8 ± 1.3 3.0 ± 3.2 6.2 ± 3.5 
0.2 mM myriocin + C 4 1.5 ± 1.3 1.5 ± 1.3 7.2 ± 4.3 10.2 ± 2.9^^## 
2 mM myriocin + C 5 3.6 ± 1.1 6.2 ± 2.2 11.6 ± 3.7^ 13.8 ± 5.3^^# 
 
Table 3.7 Number of face wash strokes after L-cycloserine or myriocin plus 
carrageenan injection. Mean ± SD of each group is shown in this table. 
Abbreviation: C: carrageenan. ^ indicates significant difference compared 
with before injection within the same treatment group (^: P<0.05; ^^: P<0.01). 
# indicates significant difference compared with 6 hours after injection within 
the same treatment group (#: P<0.05; ##: P<0.01). & indicates significant 
difference compared with 1 day after injection within the same treatment 
group (&: P<0.05). 
 
3.1.5. Effects of ICV injection of inhibitors on mice without carrageenan injection 
Several compounds were chosen to test their effects on intact mice, i.e., mice 
without facial carrageenan injection. There were no significant differences in the number 
of responses between any two groups at any time point, which meant that ICV injection 
of D609, GW4869, or L-cycloserine might not affect normal somatosensation of mice 













Injection 6H 1D 3D 
Saline 4 1.8 ± 2.4 3.0 ± 26 3.0 ± 2.2 7.2 ± 2.9 
100% DMSO 4 2.2 ± 2.2 4.2 ± 1.5 6.0 ± 4.4 3.8± 3.3 
2 mM D609 4 5.2 ± 1.7 4.5 ± 2.5 5.2 ± 1.7 7.0 ± 7.4 
2 mM GW4869 4 3.0 ± 0.0 2.8 ± 0.5 6.0 ± 3.6 8.2 ± 3.8 
2 mM L-cycloserine 4 1.8 ± 2.1 2.5 ± 1.3 2.0 ± 0.0 5.8 ± 4.1 
 
Table 3.8 Number of face wash strokes in mice without facial carrageenan 
injection. Data is shown in Mean ± SD. Mice injected with inhibitors showed 
no statistical difference in the number of face wash strokes compared with 
vehicle injected mice at any time point.  
 
3.2. ASMase activity and PC-PLC activity assay after ICV D609 injection 
D609 was chosen for further study of ASMase/ PC-PLC activity assay because it 
showed the most obvious effect in reducing allodynia caused by facial carrageenan 
injection among all inhibitors in the mice pain behavior experiment.  
No significant differences in PC-PLC activity were observed among ICV D609 
plus facial carrageenan injected mice, ICV saline plus facial carrageenan injected mice 
and untreated mice (Figure 3.6A). ASMase activity was significantly increased in the left 
SI in mice with ICV saline plus facial carrageenan injection, compared to untreated mice 
at 3 days after injection. Decreased ASMase activity was observed in all investigated 
parts of the brain, i.e. brain stem, thalamus, somatosensory cortex in the ICV D609 plus 
facial carrageenan injected mice, compared to the untreated mice and vehicle injected 
mice (Figure 3.6B). 
 































Figure 3.6 ASMase and PC-PLC activity in different parts of brain. A: No 
PC-PLC activity differences were observed among D609 plus carrageenan 
injected, saline plus carrageenan injected, and untreated mice. B: Significantly 
increased fluorescence reading was observed in the left primary somatosensory 
cortex after saline plus carrageenan injection, compared with untreated mice. 
ICV injection of D609 resulted in significant reduction in fluorescence reading 
in all the selected parts of the brain. Data is shown in Mean ± SE. n=7 for each 
treatment group. # indicates significant difference compared with untreated 
group (#: P<0.05; ##: P<0.01). * indicates significant difference compared 
with saline plus carrageenan injected group (*: P<0.05; **: P<0.01). 









































































































3.3. Effect of free radical scavenger PBN on facial allodynia 
Mice injected with carrageenan showed significantly increased face wash strokes 
on the third day after injection, indicating allodynia. The number of face wash strokes 
decreased significantly at 6 hours after ICV injection of PBN. At 1 day after ICV PBN 
injection, the number of responses slightly increased, but still significantly fewer 
compared with before ICV injection. In contrast, no significant decrease in the number of 
face wash strokes was found after ICV injection of saline. There was also a significant 
difference in the number of face wash strokes between PBN injected mice and saline 
injected mice at 6 hours after ICV injections (Figure 3.7, Table 3.9). 
 
Figure 3.7 Effect of free radical scavenger PBN on carrageenan induced facial 
allodynia. Significantly fewer face wash strokes were observed after PBN 
injection on the third post-carrageenan injection day, compared to before PBN 
injection. Mice injected with PBN also showed significantly fewer face wash 
strokes, compared to saline injected mice. # indicates significant difference 
compared to saline injected mice (P<0.05). * indicates significant fewer face 







Figure 3.7 Effect of free radical scavenger PBN on carrageenan induced facial 
allodynia. ICV PBN injection significantly reduced the number of face wash 
strokes in mice with facial allodynia. # indicates significant difference 
compared to saline injected mice at the same time point (P<0.05). * indicates 
significant difference compared with before ICV PBN injection (3 days after 






































Table 3.9 Number of face wash strokes after PBN injection. Mean ± SD of 
face wash strokes of each group is shown here. * indicates significant 
difference compared with before injection within the same treatment group (*: 
P<0.05; **: P<0.01). £ indicates significant difference compared with before 
ICV injection on the third post-carrageenan injection day, within the same 
treatment group (£: P<0.05; ££: P<0.01).  
 
3.4. Intracellular H2O2 production induced by C18 ceramide in PC12 cells 
Three hours after treatment, the amount of H2O2 produced in 100 μM C18 
ceramide treated cells was significantly higher than vehicle (DMSO) treated cells (Figure 
3.8). This effect can be inhibited by co-incubation with L-type calcium channel inhibitor 
nifedipine, free radical scavenger D609 and PBN, or mitochondria permeability transition 
pore blockers bongkrekic acid and cyclosporine A (Figure 3.9). 
Treatment n Before Injection 
3 days after 
facial carrageenan injection 1 day after 
ICV injection before ICV 
injection 
6 h after 
ICV injection 
Saline + 
carrageenan 7 3.6 ±1.3 14.1 ± 4.6** 10.1 ± 3.0** 10.3 ± 2.3** 
PBN + 
carrageenan 7 3.4 ±1.1 16.7± 3.9** 6.6 ± 3.1
££ 11.3 ± 3.6£ 
 






























Figure 3.8 C18 ceramide’s effects on intracellular H2O2 production in PC12 
cells. C18 ceramide at different concentration was added to PC12 cells. Three 
hours after addition of C18 ceramide, H2O2 produced in 100 μM C18 
ceramide treated cells was much more than vehicle (DMSO) treated cells. * 
indicates significant difference compared with DMSO treated cells (P<0.05). 
Data is shown in Mean ± SD. Abbreviation: Cer: ceramide. 
 







Figure 3.9 C18 ceramide’s effects on intracellular H2O2 production are 
affected by other factors. A: Nifedipine caused decreased H2O2 production 
induced by 100 μM C18 ceramide in PC12 cells.  B: D609, PBN, bongkrekic 
acid or cyclosporine A caused decreased H2O2 production induced by 100 μM 
C18 ceramide in PC12 cells. Abbreviations: Cer: ceramide; BKA: bongkrekic 
acid; CsA: cyclosporine A. Data is shown in Mean ± SD. # indicates 



























































The present study was carried out using inhibitors to sphingomyelinase or SPT to 
elucidate a possible role of CNS ceramide in nociception in a mouse model of orofacial 
pain. It was found that ICV injection of inhibitors to ASMase, NSMase or SPT, 
significantly reduced responses to von Frey hair stimulation at 3 days after facial 
carrageenan injection, indicating a possible role of ceramide in CNS nociception. The 
results added to a previous finding, in which peripheral injection of the sphingomyelinase 
inhibitor GW4869 markedly attenuated TNF-α-induced hyperalgesia in rats (Joseph and 
Levine 2004). No differences in the number of responses were detected before and after 
injection of inhibitors and vehicles in the absence of facial carrageenan injection. This 
suggests that these enzymes play a role during allodynia, but not normal somatosensation. 
Acid sphingomyelinase in secretory vesicles is released when the latter fuse with 
the cell membrane (Grassme et al. 1997; Grassme et al. 2001). This brings the enzyme to 
the outer leaflet of the cell membrane and its substrate, sphingomyelin (Emmelot and Van 
Hoeven 1975; Merrill and Jones 1990). In comparison, neutral sphingomyelinase is 
localized to the endoplasmic reticulum and nucleus (Fensome et al. 2000; Neuberger et 
al. 2000; Rodrigues-Lima et al. 2000; Mizutani et al. 2001) and might exert its effect at 
these locations. The observation that inhibitors to SPT inhibited allodynia also indicates a 
possible role for de novo ceramide synthesis in allodynia after facial carrageenan 
injection. The effects of the above inhibitors are expected to occur in the spinal 
trigeminal nucleus that relays pain from the orofacial region, but could also occur in other 
parts of the central pain pathway, since compounds could diffuse throughout the brain 
 






after ICV injection. Direct injection of the compounds into the brainstem was not 
attempted in this study as they could be lethal. 
From the behavior test results, it was found that ASMase inhibitor D609, was the 
one that could reduce facial allodynia most obviously. However, the anti-allodynic effect 
of D609 might be due to other effects since it is not specific. For example, it might be due 
to PC-PLC, which is also known to be involved in the development of hyperalgesia 
(Galeotti et al. 2006; Joseph et al. 2007). PC-PLC hydrolyzes phosphatidylcholine to 
produce diacylglycerol (DAG), which is an important regulator of PKC (Newton 1997). 
PKC has been shown to affect pain transmission. Intrathecal injection of PKC inhibitor 
also significantly reduced the formalin induced central sensitization (Coderre 1992) or 
substance P mediated hyperalgesia (Wajima et al. 2000) in rats. However, this possibility 
is not supported by the finding since no changes of PC-PLC activity were observed in the 
brain after ICV D609/ facial carrageenan injection. 
The possibility that D609 reduces mechanical allodynia by inhibiting ASMase is 
supported by the finding of significantly reduced ASMase activity in all the selected 
regions of the brain after D609 injection. It was also found that ASMase activity 
increased significantly in left primary somatosensory cortex (SI) after saline plus 
carrageenan injection, but not in the other selected parts of brain. The reason might be 
that the sampled region (the left and right part of medulla oblongata, ventral posterior 
nucleus of the thalamus, and primary somatosensory cortex) process non-nociceptive 
information as well as nociceptive signals.  
 






It is postulated that even minute changes of ceramide might be sufficient to 
induce significant amplification of downstream signaling molecules/ second messengers. 
Ceramide molecules have the tendency to spontaneously self associate to small 
ceramide-enriched membrane microdomains (Kolesnick et al. 2000) and these 
microdomains spontaneously fuse to large ceramide-enriched macrodomains or platforms 
(Holopainen et al. 1998; Kolesnick et al. 2000; Nurminen et al. 2002). The fusion of 
small rafts might cluster receptor molecules in the membrane raft (Roccamo et al. 1999), 
or result in conformational changes of the receptor molecules on binding to ligands. It has 
been observed that ceramide-enriched membrane platforms amplify signaling via CD95 
by around 100 folds (Grassme et al. 2003). It is postulated that increased clustering of 
glutamate receptors into lipid rafts of central nociceptive neurons could potentiate 
synaptic transmission through these neurons (Hering et al. 2003).  
Another possibility is that D609 modulates allodynia transmission due to its 
antioxidant properties. D609 is one of the derivatives of xanthates, which scavenges 
hydroxyl radicals and hydrogen peroxide, reacting with electrophilic products of lipid 
oxidation in a manner similar to glutathione (Zhou et al. 2001; Lauderback et al. 2003). It 
has been shown to reduce free radical-induced changes in synaptosomal lipid 
peroxidation, protein oxidation, intracellular ROS accumulation, and apoptosis 
(Lauderback et al. 2003; Sultana et al. 2004; Perluigi et al. 2006). The notion that CNS 
free radicals are important in inducing mechanical allodynia is supported by the fact that 
injection of the spin trap / free radical scavenger, PBN, significantly reduced mechanical 
allodynia after ICV injection. Intrathecal or ICV injection of PBN has also been shown to 
 






reduce secondary hyperalgesia caused by intradermal injection of capsaicin into the rat 
paw (Lee et al. 2007). Other studies have shown reduction in inflammatory pain after 
intrathecal injection of the SOD mimetic M40403 (Wang et al. 2004) or TEMPOL (Lee 
et al. 2007; Schwartz et al. 2008). It is proposed that caspase signaling, ROS production, 
and ceramide generation are closely associated with the pathogenesis of neuropathic and 
inflammatory pain in rats (Joseph and Levine 2004; Joseph and Levine 2006).  
In addition, ceramide and its metabolites including S1P, or Cer1P are important 
signaling molecules that not only facilitate neurotransmission (Colombaioni and 
Garcia-Gil 2004; Farooqui et al. 2007) but also modulate PLA2 and COX activities, 
which regulate the production of free radicals and ROS levels (Farooqui et al. 2007) and 
may contribute to pathogenesis of neuropathic and inflammatory pain in rats. This is 
supported by the finding that C18 ceramide directly caused an increased H2O2 production 
in PC12 cells. Furthermore, sphingomyelinase itself can also induce NO release / iNOS 
mRNA expression in cultured rat brain microglia (Yang et al. 2001). 
In conclusion, ICV injections of inhibitors that reduce CNS ceramide generation 
are effective in reducing mechanical allodynia after facial carrageenan injection. The 
results could point to a role of CNS sphingolipids and free radicals in inflammatory pain 














Chapter 3.2 Effects of Ceramides on Exocytosis and 
Intracellular Calcium Concentration 
 
 






Ceramides are a class of sphingolipids involved in diverse cellular processes such 
as apoptosis, growth arrest and differentiation (Hannun and Obeid 2002). They have a 
fatty acid chain of varied length, saturation and hydroxylation, bound to an amino group 
of a sphingoid base via amide linkage. The fatty acid chain can vary between two to 
twenty eight carbons, while C16 to C24 ceramides are the most abundant species in 
mammalian cells. Ceramides could be generated either through de novo synthesis by 
serine palmitoyltransferase or ceramide synthase, or through hydrolysis of cellular 
sphingomyelin via acid or neutral sphingomyelinases (Kolesnick and Hannun 1999). 
Ceramide and cholesterol enriched membrane platforms or “lipid rafts” on the cell 
membrane cluster receptor molecules, and recruit intracellular signaling molecules to the 
aggregated receptors (Gulbins and Li 2006). Lipid rafts also cluster members of the 
SNARE family of proteins, involved in exocytosis (Chamberlain et al. 2001; Salaun et al. 
2005; Gil et al. 2006). 
 Changes in lipid composition and conformation of cell membranes can cause 
enhanced fusion of synaptic vesicles, and release of neurotransmitters (Rossetto et al. 
2006). Such fusion of synaptic vesicles with the plasma membrane during exocytosis 
may be detected by membrane capacitance measurements under voltage-clamp 
conditions (Chen and Gillis 2000; Chik et al. 2001; Sun and Wu 2001; Di et al. 2002; 
Klyachko and Jackson 2002; Sun et al. 2002; Zhang and Zhou 2002). These 
measurements enable high time-resolution quantitation of exocytosis and 
neurotransmitter release (Sun and Wu 2001). Using this technique, it was found that 
 





external application of secretory phospholipase A2 (sPLA2) resulted in increased 
exocytosis in PC12 cells or cultured hippocampal neurons (Wei et al. 2003). Exocytosis 
can also be analyzed using total internal reflection fluorescence microscopy (TIRFM). 
The aqueous phase immediately adjacent to a glass interface is selectively illuminated in 
this technique, thus enabling direct, real time visualization of a pool of fluorescently 
labeled vesicles that are close to the cell membrane (Allersma et al. 2004). 
 Increase in several ceramide species has been shown by non-targeted lipid 
profiling (lipidomics) of the rat hippocampus after kainate lesions (Guan et al. 2006). 
Ceramide could affect the function of the cell membrane / lipid rafts, but thus far, little is 
known about whether ceramide species could have direct effect on exocytosis. The 
present study was then carried out to determine possible effects of various ceramide 
species on exocytosis in cells. 
 





2. Materials and methods 
Ceramides used in this investigation have fatty acid chains ranging from 2 to 20 
carbons and could be dissolved in dimethyl sulfoxide (DMSO) (Table 3.10). These 
ceramide species were chosen because of their ready commercial availability, and 
solubility in DMSO. Species such as C24 ceramide, which is insoluble even in DMSO, 
were not included in this study.  
Ceramides 
(Abbreviations) Full name Source 
C2 ceramide N-acetyl-D-sphingosine Sigma-Aldrich, St Louis, USA 
C6 ceramide N-hexanoyl-D-sphingosine Sigma-Aldrich, St Louis, USA 
C16 ceramide N- palmitoyl-D--erythro- spingosine 
Avanti Polar Lipids, 
Alabaster, USA 
C18 ceramide N-stearoyl-D-erythro-sphingosine Avanti Polar Lipids, Alabaster, USA 
C20 ceramide N-arachidoyl –D-erythro-sphingosine 
Avanti Polar Lipids, 
Alabaster, USA 
Table 3.10 Ceramide species used in patch clamp and TIRFM experiment. 
2.1. Cell membrane capacitance measurements 
2.1.1. Cell culture 
 PC12 cells (pheochromocytoma cells) were cultured in RPMI medium 
supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Gibco, 
Invitrogen, Carlsbad, CA). Cells were plated in 35 mm Petri dishes, and maintained in an 
incubator at 37 0C, 100% humidity, with 95% air and 5% CO2. 
 





Primary cultures of hippocampal neurons were prepared from 1 to 3-days-old 
Wistar rat pups. They were deeply anesthetized and decapitated. The brains were rapidly 
removed and transferred to 75 mm Petri dishes containing ice cold Hanks’ balanced salt 
solution. The left and right hippocampi were dissected out under sterile conditions, and 
incubated with 2 ml of 0.05% trypsin-EDTA (ethylenediaminetetraacetic acid) at 37 °C 
for 10 min. The tissues were washed twice with PBS, and then transferred into 
Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin. A cell suspension was prepared by titration with a 
flame-polished Pasteur pipette. The cells were plated on 35 mm Petri dishes at a final 
density of approximately 5105 cells per cm2. They were maintained in an incubator at 37 
°C, 100% humidity and 95% air and 5% CO2. The culture medium was changed to fresh 
medium on the second day in culture and half the medium was changed every two days. 
They were analyzed after 5-7 days. All procedures involving animals were approved by 
the Institutional Animal Care and Use Committee. 
2.1.2. Lipid raft disruption by methyl ß cyclodextrin 
 Some of the cultured cells were treated with methyl ß cyclodextrin (M-ß-CD) 
(Sigma-Aldrich, St Louis, MI) prior to the capacitance measurements. This chemical is 
known to decrease cholesterol content of the cell membrane, resulting in disruption of the 
function of lipid rafts (Ko et al. 2005; Sun et al. 2005; Shvartsman et al. 2006). M-ß-CD 
was dissolved in serum free culture medium at a concentration of 10 mM. Cells were 
incubated with 10 mM M-ß-CD in serum free culture medium for 10 min at 37 °C, and 
washed twice with PBS before patch clamp experiments. 
 





2.1.3. Solutions for patch clamp recording 
 The cell culture medium was changed to 2 ml of external solution/bath solution 
prior to the patch clamp experiments.  
The external solution/bath solution contained (in mM): 150 NaCl, 2.8 KCl, 10 
CaCl2, 1 MgCl2, 10 HEPES and 2 mg/ml glucose, pH 7.2 with 310 mOsm.  
The internal solution for glass pipettes contained (in mM): 130 K-gluconate, 2 
NaCl, 20 HEPES, 4 MgCl2• 6H2O, 4 Na2ATP•2.5H2O, 0.4 NaGTP and 1 EGTA.  
Ceramides were dissolved in DMSO to a concentration of 5 mM, and further 
diluted with external solution to a concentration of 2 mM. A solution of 40% DMSO in 
external solution was used as vehicle control. During cell membrane capacitance 
measurement, 2 µl of ceramide solution / DMSO vehicle was added to the external 
solution, near a stably “whole cell” voltage clamped cell for capacitance measurements. 
The final concentration of ceramides in the vicinity of the cell was estimated to be 2 µM. 
2.1.4. Whole-cell patch clamp recording 
Capacitance measurements during patch clamp conditions enable high 
time-resolution quantitation of exocytosis and neurotransmitter release (Sun and Wu 
2001). An EPC-9 patch-clamp amplifier was used together with the Pulse software 
package (HEKA Electronics, Germany) in capacitance measurement. Capacitance 
measurements were performed on the cells while applying ceramides externally, using 
the Lindau-Neher technique implemented as the `sine+dc' mode (Gillis 1995) of the 
software lock-in extension of Pulse. This allowed long duration capacitance 
 





measurements in a single sweep. A 1000 Hz, 50 mV peak-to-peak sinusoid voltage 
stimulus was superimposed onto a DC holding potential of -70 mV. 
Glass pipettes for the patch clamp recording had an outer diameter of 1.5 mm, and 
an inner diameter of 0.84 mm (World Precision Instruments, 1B150F-4, FL, USA). 
Pipettes were pulled into two with relatively blunt tip using a multi-stage micropipette 
puller (Sutter Instrument, Model P-97, CA, USA). Pipettes were then firepolished using a 
microforge (Narishige, MF-830, Tokyo, Japan) to promote gigaohm seals and to reduce 
the possibility of tip penetration into the cell during seal formation. 
Capacitance measurements were carried out on PC12 cells or hippocampal 
neurons under whole-cell voltage clamp conditions, using 3-7 MOhm pipettes. First, an 
individual cell with normal appearance, without bulbs attached was chosen under 
microscope for patch clamp recording. Firepolished glass pipette filled with internal 
solution was mounted and secured over a silver electrode at the pipette holder. A positive 
pressure was applied to the pipette to maintain the cleanliness of the internal walls of 
pipette as the pipette approached the cell. A manipulator was used to control the 
movement of the pipette towards the location of the selected cell. Upon touching the bath 
solution, a current response to the voltage held at the electrode was seen on the monitor. 
Once the pipette touches the cell, a gentle suction was applied until the current response 
became essentially zero with two small spikes in place of the previous start. The holding 
potential in the electrode was changed gradually to -70 mV to speed up the giga-seal 
configuration formation when the recorded resistance of the cell membrane was in the 
gigaohm range. Capacitance compensation (termed as Fast Capacitance Compensation) 
was applied to cancel capacitive currents. A further suction was applied for whole cell 
 





configuration, until similar current spikes are observed as in the case of a “giga-seal”. 
Capacitance compensation (termed as Slow Capacitance Compensation) was then applied 
to cancel this capacitive current. If the membrane resistance was still in the gigaohms 
range, the whole cell configuration was reached. Only cells that were stably voltage 
clamped were analyzed, that means, a series resistance of less than 20 mega ohms, with 
no sudden changes of more than 10%. 
  The recording of capacitance lasted for 5 seconds after addition of ceramide 
while the cell was in a “stabilized” position. The capacitance value was normalized to the 
one immediately before ceramide treatment. This was to take into account slight 
differences in initial capacitances, between cells of different sizes. Ten to thirteen cells 
were analyzed for each treatment. A non-parametric test (Spearman’s rank correlation 
test) was used to determine any correlation between capacitance and time (SPSS 12.0 for 
Windows software). A positive correlation denotes increase in membrane capacitance 
with time after application of ceramide, indicating exocytosis. P < 0.05 was considered 
significant. 
2.2. Total internal reflection fluorescence microscopy (TIRFM) 
2.2.1. Cells and plasmids 
PC12 cells were cultured in DMEM supplemented with 10% horse serum (Gibco) 
and 5% fetal bovine serum at 37 ºC and 5% CO2. Neuropeptide Y (NPY)–enhanced green 
fluorescence protein (EGFP) plasmid was a kind gift from Dr. Wolf Almers (Vollum 
Institute, Oregon Health Sciences University). Cells were plated onto poly-L-lysine 
(Sigma, St Louis, USA) coated glass coverslips and transfected with 1 µg of NPY-EGFP 
 





plasmid using SuperFect Transfection Reagent (QIAGEN GmbH, Germany), 1-2 days 
before the imaging experiments. 
2.2.2. TIRFM  
  The buffer solution contained (in mM): 150 NaCl, 5.4 KCl, 2 MgCl2, 1.8 CaCl2, 5 
mM glucose, and 10 HEPES (pH 7.4). This solution, containing 2 µM of various 
ceramide species (diluted from 2 mM stock in 40% (v/v) DMSO) or 0.04% (v/v) DMSO 
vehicle control, was infused to the imaging chamber. In the zero Ca2+ experiment, CaCl2 
was replaced by 5 mM ethylene glycol tetraacetic acid (EGTA). Total internal-reflection 
fluorescence microscopy was carried out using a Zeiss Axiovert 200 inverted microscope. 
EGFP was excited by 488 nm laser and the emission light was collected at 520 nm. 
Time-lapse digital images were acquired at 1 Hz by a CCD camera with exposure time of 
18 ms, and image stacks were analyzed using MetaMorph 6.3 software (Universal 
Imaging, Downingtown, PA). Four cells were analyzed for each treatment, except for the 
EGTA calcium chelation experiment (6 cells). 
2.3. Intracellular free calcium level measurement 
2.3.1. Cell culture 
 PC12 cells were cultured in RPMI Medium supplemented with 10% fetal bovine 
serum and 1% penicillin/ streptomycin (Gibco, Invitrogen, Carlsbad, CA). Cells were 
plated in 35 mm Fluorodish (FD35PDL, World precision Instruments, Sarasota, FL, US). 
The glass bottom of Fluorodish is coated with poly-D-lysine. Cells were maintained in an 
incubator at 37 0C, 100% humidity, with 95% air and 5% CO2. 
 





2.3.2. Intracellular calcium level measurements 
 Before the measurement of intracellular free calcium concentration ([Ca2+]i), 
PC12 cells were loaded with Fura-2-AM (Fura-2, acetoxymethyl ester) (Invitrogen, 
Eugene, OR, USA), which is a high affinity and membrane-permeable, intracellular 
calcium indicator that is radiometric and UV light excitable. Fura-2-AM was dissolved in 
anhydrous DMSO at 1 mM and stored at 4 °C in small aliquots, avoiding of light. PC12 
cells were incubated with 5 µM fura-2-AM in HEPES buffer (20 mM HEPES, 115 mM 
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 13.8 mM glucose, pH 7.4) for 1 hour 
at 37 °C. Fura-2-AM loaded cells were washed twice with HEPES buffer and incubated 
for an additional 30 minutes to allow for cellular esterase cleavage of the acetoxymethyl 
moiety and intracellular trapping of the free acid Fura-2-AM indicator.  
Intracellular free calcium level measurement was carried out by following 
previously established procedures (Pal et al. 1999; De et al. 2003) using dual wavelength 
fluorescent measurements with imaging-based detection system. Fluorodish with PC12 
cells loaded with Fura-2-AM was mounted on an Olympus IX71 inverted microscope. 
The fluorescence excitation source was a 150 W Xenon arc lamp (OptoSource Arc Lamp, 
Cairn Research Limited, Kent, UK). Alternating excitation wavelengths of 340 and 380 
nm were generated using OptoScan Monochromator (Cairn Research Limited, Kent, 
UK), and 510 nm emission was acquired using a Fura filter cube (XF-04-2, Omega 
Optical Inc., VT, USA) with a dichroic at 400 nm. Alternating emissions from 340 and 
380 nm excitation were captured with a CoolSNAP HQ2 digital CCD camera 
(Photometrics, AZ, USA). Image pairs for each wavelength were captured and digitized 
at 10 s intervals. Image acquisition and processing were computer-controlled using 
 





Metamorph software version 7.0.4. Using this image analysis software, regions of interest 
were selected for each PC12 cell in the field, on average more than 10 cells were selected 
in each dish. The ratio of emission intensity (340/380) for individual region/cell was 
calculated. The relative [Ca2+]i across time was indicated as the normalized value of 
emission intensity (340/380), that means, each value was divided by the first value of 
recording. This was to take into account possible differences in initial [Ca2+]i 
concentration in different cells. Two microliter of 2 mM C18 ceramide was added to 
fura-2-AM loaded PC12 cells at 390 s from the start of recording, the final concentration 
of C18 ceramide was estimated as 2 μM. In another group of PC12 cells, after loading 
with the fura-2-AM, PC12 cells were incubated with L-type calcium channel blocker 
nifedipine at a concentration of 1 μM in HEPES buffer for 15 min at 37 °C. Then 2 μM 
of C18 ceramide was added to fluorodish at 390 s from the start of fura-2-AM image 
recording.  
3. Results 
3.1. Capacitance measurements 
3.1.1. Capacitance changes after adding ceramides to PC12 cells 
 Significant increase in membrane capacitance with time was observed in PC12 
cells after external addition of C2, C6, and C18 ceramides (P < 0.05). This is an indicator 
of exocytosis since membrane capacitance is proportional to cell surface area and is 
increased upon fusion of secretory vesicles with the plasma membrane. In contrast, no 
increase in capacitance was observed after addition of C16 and C20 ceramides, or DMSO 
 





vehicle (Figure 3.11, Table 3.11). Figure 3.10 shows a typical recording of capacitance 
change after adding C18 ceramide to PC12 cell. 
 
 
Figure 3.10 Typical recording of capacitance changes after addition of C18 
ceramide to PC12 cell. The X axis indicates time (s). The left Y axis indicates 
membrane capacitance (F), the right Y axis indicates series resistance (Ohms). 
The pink wave represents membrane capacitance; the red wave represents 
series resistance. An average of membrane capacitance or series resistance 
was calculated every 100 ms respectively. Vertical blue line indicates the time 
point of adding ceramides to PC12 cells. There was an increase in membrane 
capacitance after adding C18 ceramide to PC12 cell. 
 






Figure 3.11 Membrane capacitance changes after adding different ceramide 
species to PC12 cells. Significant increase in capacitance was observed after 
addition of C2, C6 and C18 ceramide. Y axes indicate capacitance values 
normalized to the value before ceramide application. Values indicate mean 
and standard error. A ‘best-fit’ line was included in the plots. n = 10 to 13 






































































































































































C2 Cer 11 0.88 0.41 0.00* 
C6 Cer 12 0.82 0.35 0.00* 
C16 Cer 11 0.21 0.14 0.27 
C18 Cer 10 0.42 0.30 0.02* 
C20 Cer 13 0.76 -0.07 0.54 
DMSO 10 0.78 -0.20 0.12 
M-β-CD + C18 Cer 10 0.88 -0.00 0.98 
M-β-CD + DMSO 10 0.21 0.09 0.47 
 
Table 3.11 Effect of ceramide species on exocytosis in PC12 cells. 
Spearman’s rank correlation test was used to calculate the correlation between 
membrane capacitance and time. A positive correlation indicates increase in 
capacitance with time, and vice versa. Increase in capacitance was observed 
after addition of C2, C6 and C18 ceramide to PC12 cells. The effect of C18 
ceramide was shown to be dependent on the integrity of the lipid raft. 
Addition of the cholesterol chelating agent / disruptor of lipid rafts, methyl ß 
cyclodextrin prior to C18 ceramide treatment resulted in no significant 
increase in capacitance. P< 0.05 was considered significant (indicated by *).  
Abbreviations: Cer: ceramide; M-ß-CD: methyl ß cyclodextrin. 
 





3.1.2. Capacitance changes after adding C18 ceramide to PC12 cells depleted of 
membrane cholesterol 
 Pre-treatment of cells with 10 mM M-ß-CD resulted in non-significant increase in 









Figure 3.12 Effect of C18 ceramide on membrane capacitance in methyl ß 
cyclodextrin pre-treated PC12 cells. C18 ceramide (A) or DMSO control (B) 
could not cause capacitance increase in PC12 cells pre-incubated with methyl 
ß cyclodextrin. C: summary of capacitance changes on PC12 cells with / 
without methyl ß cyclodextrin pre-treatment, followed by addition of C18 
ceramide / DMSO. n = 10 in each treatment. Results were analyzed by 
Spearman’s rank correlation test, P< 0.05 was considered significant. 
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3.1.3. Capacitance changes after adding C18 ceramide to primary hippocampal 
neurons 
 Significant increase in membrane capacitance with time was observed in primary 
hippocampal neurons after external addition of C18 ceramide (P<0.05), the same species 
that caused the largest increase in membrane capacitance in PC12 cells. Pre-treatment of 
neurons with M-ß-CD resulted in non-significant increase in capacitance after C18 
ceramide treatment. This finding was similar with the results obtained from PC12 cells 



























Figure 3.13 Effect of methyl β cyclodextrin on membrane capacitance 
changes in neurons. C18 ceramide could not cause capacitance increase in 
methyl ß cyclodextrin pretreated hippocampal neurons. n = 10 in each case. 
Results were analyzed by Spearman’s rank correlation test. P<0.05 was 


















C18 Cer 10 0.89 0.40 0.0016* 
M-β-CD + C18 Cer 10 0.30 0.15 0.24 
 
Table 3.12 Effect of C18 ceramide on exocytosis in primary hippocampal 
neurons. Spearman’s rank correlation test was used to calculate the correlation 
between membrane capacitance and time. A positive correlation indicates 
increase in capacitance with time. Increase in capacitance was observed after 
addition of C18 ceramide to hippocampal neurons. The effect of C18 
ceramide was shown to be dependent on the integrity of the lipid raft. 
Addition of the cholesterol chelating agent / disruptor of lipid rafts, methyl ß 
cyclodextrin prior to C18 ceramide treatment resulted in no significant 
increase in capacitance. P<0.05 was considered significant (indicated by *).  
Abbreviations: Cer: ceramide; M-ß-CD: methyl ß cyclodextrin. 
 
3.2. TIRFM 
NPY-EGFP labeled subplasmalemmal vesicles were observed to fuse with the cell 
membrane, and their numbers quickly decreased after treated with C2, C6, C18 ceramide, 
indicating exocytosis. The most rapid effect was observed after addition of C18 ceramide. 
In contrast to the above species, no decrease in vesicle number was detected after 
addition of C16 or C20 ceramide, and DMSO vehicle. C18 ceramide induced exocytosis 
was Ca2+ dependent, and exocytosis was not observed in cells that were treated with this 
ceramide in the presence of the Ca2+ chelator, EGTA (Figure 3.14, Table 3.13). 
 
 















Figure 3.14. Time-lapse total internal reflection fluorescence microscopy 
(TIRFM) after application of ceramide species. A: Typical recordings of the 
footprints of living PC12 cells that had been transfected with NPY-EGFP, 
before (t = 0 s, at the left) and after (t = 30 s in the middle; t = 80 s at the 
right) addition of 2 µM C18 ceramide (top) or vehicle (0.04% v/v DMSO) 
(bottom). Upper panels: there was decrease in the number of NPY-EGFP 
labeled subplasmalemmal vesicles (bright fluorescent dots) after C18 
ceramide application indicating release of vesicles. Lower panels: no decrease 
in number of subplasmalemmal vesicles was seen after application of DMSO 
(vehicle control). Scale = 2 µm. B: Changes in number of subplasmalemmal 
vesicles after the application of C18 (), C2 (Δ) or C6 ( ) ceramide. The 
fastest response was observed after application of C18 ceramide. Its kinetics is 
an exponential (doted line) with a time constant of 20 seconds. In contrast, 
C16 (#), C20 (+) ceramide and DMSO (*) did not reduce the number of 
subplasmalemmal vesicles. Depletion of external Ca2+ completely eliminated 
the capability of C18 in triggering vesicle release (○). n = 4 in each group, 










Table 3.13 Comparison of numbers of subplasmalemmal vesicles in PC12 
cells after external application of different ceramide species. Due to slight 
differences in starting number of vesicles (NPY-EGFP labeled) between 
individual cells, the numbers of vesicles were normalized to that before 
treatment (value of 1). Results were analyzed by Student’s t-test. Decrease in 
vesicles, indicating exocytosis, was observed after addition of C2, C6, and 
C18 ceramide. The effect of C18 ceramide is dependent on external calcium 
concentration. Addition of a calcium chelator, EGTA prior to C18 ceramide 
treatment resulted in no significant effect on exocytosis. Abbreviation: Cer: 
ceramide. 
 
3.3. C18 ceramide’s effect on [Ca2+]i in PC12 cells 
Significant increase of [Ca2+]i was observed after 2 μM C18 ceramide was applied 
to non-pretreated PC12 cells. [Ca2+]i peaked at 20-30 seconds after the addition of C18 
ceramide. No change of [Ca2+]i was observed after addition of C18 ceramide to PC12 
cells that were pretreated with 1 μM nifedipine. At 420 seconds, there was significant 
difference in [Ca2+]i between non-pretreated cells and nifedipine pretreated cells (P< 
Treatment n Before treatment 
30 s after 
treatment 
P value 
C2 Cer 4 1 0.7755 < 0.01 
C6 Cer 4 1 0.8154 < 0.01 
C16 Cer 4 1 1.0333 0.28 
C18 Cer 4 1 0.5109 < 0.01 
C20 Cer 4 1 0.9458 0.09 
DMSO 4 1 1.0226 0.31 
EGTA + C18 Cer 6 1 0.9648 0.20 
 





0.01), indicating C18 ceramide’s effect on [Ca2+]i is dependent on L-type calcium 
channel (Figure 3.15). 
 
Figure 3.15 Changes of intracellular calcium level after addition of C18 
ceramide to PC12 cells. A significant increase of [Ca2+]i was observed after 2 
μM C18 ceramide was added to non-pretreated PC12 cells (n= 13). [Ca2+]i 
peaked at 20-30 seconds after C18 ceramide treatment. No change of [Ca2+]i 
was observed after addition of C18 ceramide to L-type calcium channel 
inhibitor nifedipine (1 μM) pretreated PC12 cells (n= 17). At 420 seconds, 
there was significant difference in [Ca2+]i between non-pretreated cells and 
nifedipine pretreated cells (P< 0.01), indicating C18 ceramide’s effect on 
[Ca2+]i is dependent on L-type calcium channel. 
 
4. Discussion 
The present study was carried out to determine the effects of various ceramide 
species on exocytosis and possible underlying mechanism. It was found that C2, C6 and 
C18 ceramides were effective in triggering exocytosis in PC12 cells, evident by more 
than 1% increase in membrane capacitance. Similar increase in membrane capacitance 
was also observed in hippocampal neurons after C18 ceramide treatment, the same 
species which caused most significant exocytosis in PC12 cells. C16 and C20 ceramide 
did not show a tendency to cause any changes in membrane capacitance. The ability of 
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C2, C6 and C18 ceramides to induce exocytosis was confirmed, using TIRFM. These 
species caused rapid decrease in number of NPY-EGFP labeled subplasmalemmal 
vesicles, indicating exocytosis. The above results show that any effect of particular 
ceramide species on exocytosis is highly dependent on the exact length of the fatty acid 
chain.  
Ceramide has been shown to affect the physical properties of artificial lipid 
membrane. Treatment of model membrane containing sphingomyelin, 
phosphatidylethanolamine and cholesterol with sphingomyelinase, generated ceramides 
within seconds, accompanied by vesicle aggregation or efflux of intravascular 
components (Ruiz-Arguello et al. 1998). Likewise, external- and enzymatically produced 
ceramides induce release of contents from vesicles which consist of phospholipids and 
cholesterol (Montes et al. 2002). On the other hand, endocytic vesicles were observed in 
macrophages when treated with exogenous sphingomyelinase or ceramide (Zhang et al. 
1998). Ceramides have also been shown to induce pore formation in model phospholipids 
bilayers (Siskind and Colombini 2000). In addition, ceramides could affect the movement 
of proteins into or from rafts, or cause conformational changes in membrane-associated 
proteins (Cremesti et al. 2002). SNARE complex proteins are clustered in lipid rafts 
(Chamberlain et al. 2001; Salaun et al. 2005; Gil et al. 2006), and it is possible that 
changes in their conformation as a result of alteration in ceramide content could affect 
exocytosis. 
A possible role of lipid rafts in the effects of C18 ceramide was studied, using 
PC12 cells and hippocampal neurons that had been treated with M-ß-CD. The latter binds 
cholesterol, and is well known to disrupt the function of lipid rafts (Ko et al. 2005; Sun et 
 





al. 2005; Shvartsman et al. 2006). C18 ceramide induced a significant increase in 
capacitance after external application to PC12 cells/ hippocampal neurons, but no 
significant increase was observed after C18 ceramide treatment when cells were 
pre-incubated with M-ß-CD. This suggests that the increase in capacitance was dependent 
on the integrity of lipid rafts. It could involve calcium sensors associated with SNARE 
complex proteins in lipid rafts (Chamberlain et al. 2001; Salaun et al. 2005; Gil et al. 
2006), since C18 induced exocytosis was also found to be dependent on external calcium. 
The ceramide species which most significantly increases cell membrane 
capacitance and decreases subplasmalemmal vesicles, i.e., C18 ceramide, was chosen for 
study further the effect of ceramide on calcium channel. It was found that C18 ceramide 
could cause an increase of intracellular calcium concentration in PC12 cells and this 
effect was found to be L-type calcium channel dependent, which further supports the idea 
that C18 ceramide-induced exocytosis is calcium dependent.  
C18 is also the ceramide species that showed the greatest increase, by 
non-targeted lipid profiling analysis (lipidomics) of the rat hippocampus after 
kainate-induced excitotoxic injury (Guan et al. 2006). It is postulated that C18 ceramide 
might facilitate exocytosis of glutamate from damaged neurons, thus propagating 
neuronal injury. Treatment of hippocampal slices with inhibitors of ceramide 
biosynthesis resulted in attenuation of increased C18 ceramide levels, and partial 
protection against neuronal death, after kainate injury (He et al. 2007). Further studies are 
necessary to elucidate the precise effect of various ceramide species on the 
physicochemical properties on cell membranes or the function of membrane raft-related 











Chapter 3.3 Role of Central Nervous System Peroxynitrite in a 
Mouse Model of Orofacial Pain
 







Nitric oxide (NO) is a gaseous mediator involved in a variety of physiological 
functions (Schuman and Madison 1994; Moncada 1997). It is produced from L-arginine 
by nitric oxide synthases (NOS) and is involved in a variety of physiological processes in 
the cardiovascular, immune and nervous systems. Decreased NOS expression has been 
shown in the trigeminal ganglion but accumulation of the enzyme at the injury site occurs 
after inferior alveolar nerve injury (Leong et al. 2000; Davies et al. 2004). In contrast, 
increased numbers of NOS positive neurons are present in the spinal trigeminal nucleus 
after hyperalgesia induced by formalin injection (Leong et al. 2000), or loose ligation of 
the trigeminal nerve (Yonehara et al. 2003).  
NO is involved in macrophage cytotoxicity and nociceptive signaling. Injury to 
the distribution area of the trigeminal nerve has been shown to result in changes in NO 
amount at the injury site or the trigeminal ganglion. Increased levels of NO are present in 
synovial fluid of the painful temporomandibular joints (Suenaga et al. 2001; Arinci et al. 
2005). NO produced in the trigeminal nucleus likely plays a role in nociceptive 
transmission, since increased levels of excitatory amino acids are detected in the spinal 
trigeminal nucleus after nerve ligation, which could be inhibited by local infusion of the 
NO scavenger, carboxyl PTIO (Fujita et al. 2004). On the other hand, cGMP formed by 
NO could have an anti-nociceptive effect (Ferreira et al. 1991; Duarte et al. 1992).  
NO could also combine with the superoxide radical in macrophages to form 
peroxynitrite (ONOO-), a highly toxic and reactive intermediate (Radi et al. 1991; Lipton 
 






et al. 1993; De Groote et al. 1995). The latter could affect neuronal proteins, resulting in 
changes in nociceptive responses. Peroxynitrite and its derivates can oxidize and nitrate 
lipids (Radi et al. 1991), proteins (Ischiropoulos and al-Mehdi 1995), and DNA (Spencer 
et al. 1996; Szabo et al. 2007). This could affect the function of signaling molecules in 
the CNS. It has been shown that nitration of glutamate transporters by peroxynitrite 
inhibits their ability to transport glutamate from the synaptic cleft to the neurons where it 
is then metabolized to non-toxic glutamine by glutamine synthase (Kennedy et al. 1974). 
The latter can also be nitrated by peroxynitrite and lost its enzymatic activity (McBean et 
al. 1995; Minana et al. 1997; Gorg et al. 2005). These reactions result in the accumulated 
glutamate in the synaptic cleft, leading to neurotoxicity. 
It is postulated that microglia in the nociceptive pathway could be activated in 
response to neuronal activity (Bessis et al. 2007), leading to peroxynitrite formation and 
effects on nociceptive transmission. An elevated activation of microglia / macrophage has 
also been observed in its nucleus, after formalin injection (Yeo et al. 2001). It is, 
however, unclear whether the increased peroxynitrite could lead to any changes in 
nociception. The present study was therefore carried out, using intracerebroventricular 
(ICV) injection of ONOO- donor or scavenger into the third ventricle of brain, to 
elucidate the effect of CNS peroxynitrite on nociception, in a facial carrageenan injection 
induced orofacial pain model (Yeo et al. 2004).  
 






2. Materials and methods 
2.1. Chemicals 
3-Morpholinosydnonimine, HCl (SIN-1), 5,10,15,20-Tetrakis (4-sulfonatophenyl) 
porphyrinato iron (III), chloride (FeTPPS) were purchased from Calbiochem, San Diego, 
USA. They were freshly prepared and dissolved in isotonic saline. 
SIN-1 is an active metabolite of molsidomine that decomposes spontaneously in 
solution in the presence of oxygen, releasing NO and superoxide radical under 
physiological conditions (Hogg et al. 1992). The NO and superoxide radical combine 
nearly instantaneously to form ONOO- and SIN-1 is therefore used as an ONOO- donor 
(Lipton et al. 1993). FeTPPS is a ferric porphyrin complex that catalytically isomerizes 
ONOO- to nitrate both in vitro and in vivo. It thus serves as a selective ONOO- scavenger 
and decomposition catalyst. Intravenous injection of FeTPPS is effective in reducing 
edema and nitrate formation 6 hours after paw carrageenan injection in rats (Salvemini et 
al. 1998b). FeTPPS does not complex with NO and exhibits minimal SOD mimetic 
activity (Misko et al. 1998; Imam et al. 2000). 
2.2. Animals and treatment 
Altogether 69 adult male C57BL/6J mice, about 6-8 weeks of age and weighing 
approximately 20-30 g each were purchased from the Laboratory Animals Centre, 
Singapore. These mice were randomly divided into 12 groups (4 to 8 mice per group). 
Nine groups were used to study the effects of ONOO- donor/scavenger on carrageenan 
induced facial allodynia. 3 groups were used for effect of ONOO- donor/scavenger on 
 






normal somatosensation (Table 3.14). All these mice were assessed for behavioral 
responses to von Frey hair stimulation to the carrageenan injected area in face, at 1 day 










Table 3.14 Treatment group of C57BL/6J mice. Abbreviation: CA: facial 
carrageenan injection. 
 
The higher doses of SIN-1 (50 µg) used in ICV injections were chosen based on 
the estimated proportion of the size of the mouse to rat brain. It was half the highest 
concentrations used in previous studies on intrathecal or ICV injections in rats (Okada et 
al. 2002). Since FeTPPS has never been administered centrally into the cerebrospinal 
fluid, four different doses (0.5 µg, 1.5 µg, 3.0 µg and 7.5 µg), equivalent to 1/30, 1/10, 
Treatment Amount injected (ICV) n 
With CA 
SIN-1 
2  μg 4 
50  μg 8 
FeTPPS 
0.5 μg 4 
1.5 μg 6 
3.0 μg 5 
7.5 μg 7 
SIN-1 + FeTPPS 50 μg + 7.5 μg 4 
Saline 5 μl 7 
CA injection only  7 
Without 
CA 
SIN-1 2 μg 6 
FeTPPS 1.5 μg 7 
Saline  4 
Summary  12 groups 69 mice 
 






1/5 and ½ of the lethal dose (15 µg, as determined from the pilot experiment) were tested 
in this study. The half-life of the drug in the CNS is unknown, but is assumed to be 
similar to the periphery, hence, behavioral testing was carried out 6 hours after injection 
(see below).  
All measures were taken to minimize pain or discomfort, and experiments were 
conducted in accordance with international standards on animal welfare and compliant 
with standards defined by the European Communities Council Directive of 24 November 
1986 (86/609/EEC). 
2.3. von Frey hair stimulation  
The method of behavioral assessment was the same as previously described 
(details in chapter 3.1, page 49-51). Mice were assessed for behavioral responses to von 
Frey hair (~ 1 g force) stimulation to the right maxillary area at 1 day before injections, 
and at 6 hours, 1 day and 3 days after injections. The total number of face wash strokes 
after 20 probes was noted for each mouse, and the mean and standard deviation of each 
group were calculated. Possible differences between the means were elucidated using 
one-way ANOVA with Bonferroni's multiple comparison post hoc test, or Student’s t-test 
(SPSS 12.0 for Windows software). P < 0.05 was considered significant. 
2.4. ICV injections and facial carrageenan injections 
The method of injections was the same as previously described (details in chapter 
3.1, page 51). Five microliter of solution was delivered to the right lateral ventricle of 
mouse via ICV injection. The concentration for each treatment is shown in Table 3.14. 
 






Fifty microliter of carrageenan suspension (40 mg/ml in saline) was injected 
subcutaneously into the right maxilla area of the mice to study effects of the above 
chemicals on allodynia. 
3. Results 
3.1. Effect of facial carrageenan injection on control groups  
 Mice injected with carrageenan alone, showed significantly increased number of 
face wash strokes at 6 hours (13.4 ± 2.6), 1 day (18.3 ± 2.4) and 3 days (16.7 ± 3.5) after 
injections, compared with before injections (3.9 ± 2.3) (Figure 3.16A). 
Mice injected with saline plus carrageenan showed significantly increased number 
of face wash strokes at 6 hours (14.6 ± 7.4) and 3 days (20.9 ± 5.7) after injections, 
compared with before injections (5.9 ± 2.7) (Figure 3.16B). 
 













Figure 3.16 Effect of facial carrageenan injection on control groups. Effect of 
facial carrageenan injection (A), or ICV saline injection plus facial 
carrageenan injection (B) at different time point is shown (Mean ± SD). Mice 
in both groups showed significantly increased face wash strokes after facial 
carrageenan injections. * indicates significant difference compared with 
before injection (*: P<0.05; **: P<0.01). # indicates significant difference 
compared with 6 hours after injection (##: P<0.01). & indicates significant 
difference compared with 1 day after injection (&: P<0.05). 
 
3.2. Effect of ONOO- scavenger on carrageenan injected mice  
 There were no statistical significant differences in the number of face wash 
strokes among groups before treatment, i.e., the starting values were matched.  
At 6 hours after injections, mice injected with 1.5 µg, 3.0 µg, or 7.5 µg FeTPPS 
plus carrageenan showed significantly fewer face wash strokes, compared to control mice 
injected with carrageenan alone or saline plus carrageenan. Those injected with 0.5 µg of 
FeTPPS showed no significant difference in number of face wash strokes, compared to 
controls.  
At 1 day after injections, mice injected with 1.5 µg FeTPPS plus carrageenan 
showed significantly fewer face wash strokes, compared to those injected with 
carrageenan alone (Figure 3.17). The number of face wash strokes at different time point 











































































0.5ug FeTPPS + C
1.5ug FeTPPS + C
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Figure 3.17 Effect of ONOO- scavenger on carrageenan induced facial 
allodynia. Mice injected with 1.5 μg, 3.0 μg, or 7.5 μg FeTPPS plus 
carrageenan showed significantly fewer face wash strokes at 6 hours after 
injection, compared to control mice. Mice injected with 1.5 µg FeTPPS plus 
carrageenan showed significantly fewer face strokes compared to those 
injected with carrageenan alone at 1 day post-injection. Abbreviation: C: 
carrageenan. * indicates significant difference compared with facial 
carrageenan injected mice (*: P<0.05; **: P<0.01). # indicates significant 













Table 3.15 Number of face wash strokes after FeTPPs plus carrageenan 
injection. The Mean ± SD of the number of face wash strokes in each group at 
different time point is presented in this table. Abbreviation: C: carrageenan. ^ 
indicates significant difference compared with before injection within the 
same treatment group (^: P<0.05; ^^: P<0.01). # indicates significant 
difference compared with 6 hours after injection within the same treatment 
group (#: P<0.05; ##: P<0.01). & indicates significant difference compared 
with 1 day after injection within the same treatment group (&: P<0.05). 
 
3.3. Effect of ONOO- donor on carrageenan injected mice  
No difference in the number of face wash strokes was found between SIN-1 
injected mice and control mice at any time point (Figure 3.18). The number of face wash 
strokes among different time point in each group is shown in Table 3.16. 
Treatment n Before Injection 6H 1D 3D 
C 7 3.9 ± 2.3 13.4 ± 2.6^^ 18.3 ± 2.4^^## 16.7 ± 3.4^^ 
Saline + C 7 5.9 ± 2.7 14.6 ± 7.4^ 13.0 ± 3.8^^ 20.9 ± 5.7^^& 
0.5 μg FeTPPS + C 4 8.5 ± 1.7 7.5 ± 1.9 13.0 ± 2.4^## 14.5 ± 4.0^# 
1.5 μg FeTPPS + C 6 3.5 ± 2.6 2.7 ± 2.5 7.2 ± 4.5## 16.2 ±7.0^^##& 
3.0 μg FeTPPS + C 5 3.4 ± 2.7 3.2 ± 1.9 12.4 ± 4.6^^# 16.8 ± 8.0^^# 
7.5 μg FeTPPS + C 7 3.6 ± 2.3 3.3 ± 3.0 11.0 ± 3.3^## 17.0 ± 2.9^^##& 
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Figure 3.18 Effect of ONOO- donor on carrageenan induced facial allodynia. 
No difference in the number of face wash strokes was found between SIN-1 
injected mice and control mice. Abbreviation: C: carrageenan.  
 
Treatment n Before Injection 6H 1D 3D 
C 7 3.9 ± 2.3 13.4 ± 2.6^^ 18.3 ± 2.4^^## 16.7 ± 3.4^^ 
Saline + C 7 5.9 ± 2.7 14.6 ± 7.4^ 13.0 ± 3.8^^ 20.9 ± 5.7^^& 
2 μg SIN-1 + C 4 7.0 ± 3.2 9.5 ± 4.5 12.8 ± 7.9 22.2 ± 8.2^##&& 
50 μg SIN-1 + C 8 4.5 ± 2.2 8.5 ± 7.4 12.1 ± 5.8^^ 25.0 ± 4.9^^##&& 
Table 3.16 Number of face wash strokes after SIN-1 plus carrageenan 
injection. The Mean ± SD of the number of face wash strokes in each group at 
different time point is shown. Abbreviation: C: carrageenan. ^ indicates 
significant difference compared with before injection within the same 
treatment group (^: P<0.05; ^^: P<0.01). # indicates significant difference 
compared with 6 hours after injection within the same treatment group (#: 
P<0.05; ##: P<0.01). & indicates significant difference compared with 1 day 
after injection within the same treatment group (&: P<0.05; &&: P<0.01). 
Before Injection 
 






3.4. Effect of ONOO- donor or ONOO- scavenger on mice without carrageenan 
injection  
There were no significant differences in the number of face wash strokes among 
groups at any time point (Table 3.17). 
Treatment n Before Injection 6H 1D 3D 
Saline 4 6.2 ± 3.8 5.5 ± 3.1 9.2 ± 2.9 12.8 ± 1.0 
2 μg SIN-1 6 7.2 ± 4.4 8.0 ± 5.1 10.0 ± 5.9 14.5 ± 6.0 
1.5 μg FeTPPS 7 8.0 ± 1.7 7.0 ± 2.6 12.3 ± 6.6 13.6 ± 5.2 
Table 3.17 Number of face wash strokes after SIN-1/ FeTPPs injection in 
mice without facial carrageenan injection. Mean ± SD of the number of face 
wash strokes in each group at different time point is presented here. 
 






3.5. Effect of the co-injection of the donor and scavenger of ONOO- on facial 
carrageenan injected mice  
There was no significant difference in the number of face wash strokes among the 
treated groups at any time point (Table 3.18).  
Treatment n Before Injection 6H 1D 3D 
C 7 3.9 ± 2.3 13.4 ± 2.6^^ 18.3 ± 2.4^^## 16.7 ± 3.4^^ 
Saline + C 7 5.9 ± 2.7 14.6 ± 7.4^ 13.0 ± 3.8^^ 20.9 ± 5.7^^& 
50 μg SIN-1 + 
7.5 μg FeTPPS + C 4 7.8 ± 2.1 11.2 ± 10.0
^^ 14.0 ± 4.1^ 16.5 ± 3.1^^ 
 
Table 3.18 Number of face wash strokes after co-injection of SIN-1 and 
FeTPPs in facial carrageenan injected mice. The Mean ± SD of the number of 
face wash strokes in each group at different time point is shown in the table. 
Abbreviations: BI: before injection; C: carrageenan. ^ indicates significant 
difference compared with before injection within the same treatment group (^: 
P<0.05; ^^: P<0.01). # indicates significant difference compared with 6 hours 
after injection within the same treatment group (##: P<0.01). & indicates 
significant difference compared with 1 day after injection within the same 
treatment group (&: P<0.05) 
 







The present study aimed to elucidate effects of CNS peroxynitrite on a mouse 
model of orofacial pain. Facial carrageenan injection was carried out in conjunction with 
ICV injection of an ONOO- donor, SIN-1 or an ONOO- scavenger, FeTPPS, to test 
possible effects of ONOO- on nociceptive transmission in facial allodynia. Mice that 
received ICV injection of three higher doses of FeTPPS (1.5 µg, 3.0 µg, or 7.5 µg), plus 
facial carrageenan injection showed significantly fewer face wash strokes to von Frey 
hair stimulation to the carrageenan injected area in right face, compared to control mice 
that received ICV saline plus facial carrageenan injection, or facial carrageenan injection 
only. In contrast, mice injected with SIN-1 plus carrageenan, showed no significant 
difference in the number of face wash strokes, compared to controls. These observations 
suggest that scavenging of ONOO- can result in an anti-nociceptive effect on facial 
allodynia, even though administration of excess ONOO- did not significantly increase the 
nociceptive effect. Studies on SIN-1 in the spinal cord have also reported a somewhat 
ambiguous effect, in that low doses of SIN-1 reduced, whereas higher doses had no effect 
or increased, mechanical allodynia after chronic ligature of the sciatic nerve in rats 
(Sousa and Prado 2001; Kina et al. 2005).  
The intracerebroventricular injection of SIN-1 or FeTPPS would result in 
diffusion of these compounds to different parts of the brain via the cerebrospinal fluid 
circulation, and possible actions at different levels of the pain pathway.  
 






The finding that an ONOO- scavenger causes a reduction in pain responses is 
consistent with the results of a recent study which showed that intrathecal injection of a 
SOD mimetic, M40403 (a compound that converts O2- to H2O2) reduced hyperalgesia 
induced by carrageenan injection to the paw in rats (Wang et al. 2004), or intrathecal 
injection of NMDA (Muscoli et al. 2004). Orally administered FeTPPS was also recently 
shown to reduce allodynia in a diabetic mouse model (Obrosova et al. 2005).  
 However, the present results also showed that FeTPPS would not produce the 
same anti-allodynic effect in mice without facial carrageenan injection, as in facial 
carrageenan injected mice. This suggests that scavenging of ONOO- does not affect the 
basal mechanical sensation in normal mice. The anti-allodynic effect of FeTPPS could be 
reversed by co-administration of ONOO- donor SIN-1 in carrageenan injected mice. 
These data serve as positive controls, and provide indirect evidence that doses of SIN-1 
used in the present study were effective in forming ONOO- in the brain. 
In conclusion, the results of the present study suggest that ONOO- plays a role in 
nociceptive transmission in orofacial pain. Scavenging of ONOO- in the CNS can reduce 





















Growing evidences have indicated an important role of CNS lipid mediators and 
RNS in augmenting the sensitivity of sensory neurons and enhancing pain perception. It 
is unclear whether these could also play a role in other forms of increased neuronal 
excitation, such as orofacial allodynia. The main aim of the present study was to evaluate 
possible effects of CNS ceramide and ONOO- in nociception in a mouse orofacial 
allodynia model induced by facial carrageenan injection. 
The orofacial pain model of the present study was induced by subcutaneous 
injection of λ-carrageenan to the right maxilla area of mice, which has been widely used 
in orofacial pain studies (Yeo et al. 2004; Vahidy et al. 2006). Carrageenan injection 
produces inflammation, hypersensitivity, and some apparent spontaneous pain with a 
peak effect at 3–5 hours after injection to the rat hind paw (Tonussi and Ferreira 1992), 
and persists for at least one week. Directed facial grooming, i.e. uninterrupted series of 
face wash strokes directed to the stimulated maxillary area, was used as the indicator of 
unilateral facial pain in freely moving mice in the present study (Vos et al. 1998). To 
ensure that the experimental methods are consistent and comparable, all chemicals that 
are involved in the nociception signaling processes have been administered to mice via 
ICV injection since some of them cannot cross the blood brain barrier.  
A flow chart showing the experimental design and main findings of the present 
study was plotted in order to have an overall view of the central theme of the present 
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It is postulated that ceramide might be an important signaling molecule in 
nociception in the CNS. ICV injection of inhibitors to enzymes involved in ceramide 
synthesis was used to investigate possible role of ceramide in orofacial allodynia. Mice 
received ICV injection of inhibitors to ASMase, NSMase, or SPT showed a significantly 
reduced face wash strokes compared with vehicle injected mice, at 3 days after injection, 
indicating that the reduction of ceramide synthesis has an anti-allodynic effect in 
carrageenan induced facial allodynia. Among these inhibitors, ASMase inhibitor D609 
showed the most significant anti-allodynic effect. These results indicate that ceramide 
plays an important role in nociception in orofacial pain. 
The ASMase inhibitor D609 used in the behavior study could also inhibit 
PC-PLC. However, enzyme activity assay showed no change in PC-PLC activity in brain 
after facial carrageenan / ICV D609 injection, suggesting that D609’s anti-allodynic 
effect is not via the action of PC-PLC. An increased ASMase activity was observed in the 
left primary somatosensory cortex at 3 days after facial carrageenan injection. D609 
injected mice had reduced ASMase activity in all parts of brain examined (i.e., left and 
right brain stem, thalamus, and primary somatosensory cortex). These results indicated 
that D609’s anti-allodynic effect might be due to ASMase and reduced production of 
ceramide. It is postulated that ceramide is an upstream cascade signaling molecule with 
the ability to amplify downstream signaling molecules/ second messengers at very low 
concentration. Another possibility might be that D609 modulates allodynia transmission 
due to its antioxidant properties. Recent studies have shown that D609 is widely used as a 
 
 






free radical scavenger since it has a very similar structure with glutathione (Zhou et al. 
2001; Lauderback et al. 2003; Sultana et al. 2004; Perluigi et al. 2006).  
The role of free radicals in nociception was confirmed by the observation that 
ICV injection of PBN, a free radical spin trap, significantly reduced allodynia in facial 
carrageenan injected mice. A possible interaction between ceramide and free radicals was 
also investigated. It was found that incubation of PC12 cells with C18 ceramide led to a 
significant increase of hydrogen peroxide production. This effect could be inhibited by 
co-incubation with the L-type calcium channel inhibitor (nifedipine), free radical 
scavenger (D609 or PBN), or mitochondria permeability transition pore blockers 
(bongkrekic acid or cyclosporine A). It has been observed that ceramide and its 
metabolites modulate PLA2 and COX activities, which regulate the production of free 
radicals and ROS levels (Farooqui et al. 2007) and may contribute to pathogenesis of 
neuropathic and inflammatory pain in rats. The complicated interplay and cross-talk 
between glycerophospholipid- and sphingolipid-derived lipid mediators along with 
oxidative stress is shown in a hypothetical diagram (Figure 4.2).  
 
 







Figure 4.2 Hypothetical diagram showing interplay and cross-talk between 
glycerophospholipid- and sphingolipid-derived lipid mediators along with 
oxidative stress (modified from Farooqui et al. 2007 and Farooqui et al. 
2010). Abbreviations: PM: plasma membrane; SMase: sphingomyelinase; 
cPLA2: cytosolic phospholipase A2; SPT: serine palmitoyltransferase; 
COX-2: cyclooxygenase-2; Ceramide-1-P: ceramide 1- phosphate; 
Sphingosine-1-P: sphingosine 1- phosphate. ROS: reactive oxygen species. 
Plus sign indicates stimulation. 
Electrophysiological studies (patch clamp) showed that ceramide has the ability to 
increase cell membrane capacitance in PC12 cells and hippocampal neurons, indicating 
exocytosis. Total internal reflection fluorescence microscopy experiments found that, 











































membrane, and the number of vesicles quickly decreased. Both experiments found that 
C18 ceramide is the one that increases exocytosis most significantly. C18 ceramide 
induced exocytosis was also found to be dependent on extracellular Ca2+ and the integrity 
of the lipid raft. These results showed that ceramide might affect nociception in the CNS 
by inducing exocytosis of neurons directly. 
It is postulated that the role of ceramide in exocytosis is largely determined by its 
unique structure. The generation or release of ceramide leads to changes of the structure, 
fluidity, and/or permeability of the cell membrane, which in turn leads to conformational 
changes of membrane-associated enzymes or receptors, ion influx, and activation of 
specific local signaling cascade. The concept that ceramide induces ion influx was also 
confirmed by the present experiments. It was observed that C18 ceramide caused an 
increase of intracellular calcium concentration shortly after treatment. This effect was 
also found to be dependent on the L-type calcium channel. 
Last, there is also evidence that other forms of free radicals such as RNS mediate 
pain perception. RNS species such as peroxynitrite (ONOO-) and its derivates can oxidize 
lipids, nitrate proteins and cause damages to DNA, leading to changes in the function of 
signaling molecules. Animal behavior studies showed that ICV injection of ONOO- 
scavenger FeTPPS significantly reduced the number of face wash strokes in carrageenan 
injected mice, at 3 days after injection. The effect of FeTPPS can be diminished by 
co-ICV injection with an ONOO- donor SIN-1. These results show that scavenging of 
ONOO- in the CNS can reduce orofacial allodynia caused by facial carrageenan injection. 
 
 






Some promising results have been introduced and developed in the present thesis. 
This investigation might provide a pharmacological basis validating the approach of 
developing new drugs in the management of pain. For example, it is already known that 
murine models of opioid tolerance are important for investigating the underlying 
mechanisms of this phenomenon. Inhibition of ceramide biosynthesis is found to be able 
to attenuate oxidative stress, which might be crucial for elucidating mechanisms of opioid 
tolerance in its management of chronic pain (Ndengele et al. 2009). Fabry’s disease, 
where sphingolipids deposit in blood vessels and nerves, can manifest as severe 
acroparasthesia and pain. Current therapy consists of expensive enzyme replacement 
which limits its wide application to patients (Pierre-Louis et al. 2009). The work here 
may be of relevance to future research in its treatment of pain aspects. 
However, there are some issues to be explored and solved for understanding the 
role of lipid mediators and free radicals in pain perception in the future. First, it was 
found that decreasing ceramide production in the CNS has an anti-allodynic effect, 
however, whether increased ceramide production in the CNS could increase allodynia 
need to be investigated. Second, ceramide might affect nociception via increasing 
exocytosis of neuron directly, or causing conformational changes of the cell membrane, 
or as an up-stream signaling molecule in nociception processes. However, it is also 
possible that the allodynic effect of ceramide is due to its effect in regulating oxidative 
stress. The possible role of ceramide in inducing oxidative stress in the CNS can be 
examined in the future. Third, scavenging of ONOO- in the CNS can reduce orofacial 
allodynia in carrageenan injected mice. Is this because of the excess ONOO- produced in 
 
 






the CNS after facial carrageenan injection? Thus a study on whether facial carrageenan 
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